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1 Introduction 
Diabetes mellitus is the most common metabolic disorder characterized by the 
hyperglycemia and general metabolic disruption of regulatory and signaling pathways in the 
body. Pathophysiological changes may include neuropathy, vasculopathy, micro- and 
macroangiopathy, especially in the legs. These disorders cause tissue hypoxia and ischemia of 
peripheral tissues. The condition may result in poorly healing chronic wounds, venous ulcers, 
bedsores, diabetic foot syndrome, and eventually in tissue necrosis. As a result of impaired 
wound repair, patients’ quality of life and prognosis is reduced. Recently, new procedures 
have been developed for treating complicated wounds. One possibility is to use hyaluronic 
acid. This glycosaminoglycan has a clinically beneficial effect on wound healing and is a 
component of various products used for wound treatment. Hyaluronic acid supports tissue 
hydration, interacts with several receptors, and affects the cells, extracellular matrix and 
factors regulating wound healing. 
 
2 Aims 
The aim of this work was to study mechanism of the action of hyaluronic acid-iodine 
complex in the models of experimental rat wounds and also to study molecular changes 






3 Actual status of knowledge 
3.1 Description of wound healing process 
Wound healing is a process that occurs after the damage to body tissues. This work 
deals with the healing of skin wounds, which heal by tissue repair and not by regeneration (Li 
et al. 2007). Healing of skin wounds takes place in stages, which normally follow each other 
and overlap each other (Clark 1996; Li et al. 2007), Fig. 1. 
 
Fig. 1: Phases of normal wound healing. Limits vary within faded intervals, mainly by wound size and 
healing conditions. Author - Mikael Häggström, picture is in public domain via Wikimedia Commons. 
http://commons.wikimedia.org/wiki/File:Wound_healing_phases.svg 
3.1.1 Coagulation and provisional matrix formation  
After the breach of the tissue, the contact activation of Hageman factor (factor XII) by 
platelet derived polyanionic polyphosphates occurs. The subsequent launch of the intrinsic 
coagulation pathway takes place involving factors such as kininogen (source of bradykinin), 
prekalikrein, factor XI and factor X (Muller et al. 2009). Furthermore, there occurs so-called 
extrinsic coagulation pathway, which has a significant role in the repair. Factors IX and X are 
activated by the complex of tissue factor (TF) and factor VII (Nemerson 1988). TF is located 
on the surface of extravascular stromatic cells such as fibroblasts. 
Degranulated activated platelets release molecules that are constituents of a 
provisional matrix. The provisional matrix is a mixture of fibrin fibers, fibronectin, 
vitronectin, thrombospondin, tenascin and other glycoproteins. They all serve as adhesion 
molecules for the attachment and migration into the wound (Yamada et al. 1996). The 
platelets are also releasing platelet derived growth factor (PDGF), transforming growth factor 
(TGF) alpha and beta (Nečas 2005), and other pro-inflammatory factors such as serotonin, 
bradykinin, prostaglandins, prostacyclins, thromboxane and histamine (Stadelmann et al. 
1998). 
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The tissue-type and urokinase-type plasminogen activators (PA) are released from 
endothelial cells after the completion of coagulation factors release. PAs initiate the 
conversion of plasminogen to plasmin (Loskutoff et al. 1986). 
3.1.2 Vasoconstriction  
Immediately after a blood vessel is breached, ruptured cell membranes release 
inflammatory factors like thromboxanes and prostaglandins that cause the vessel to spasm to 
prevent blood loss and to collect inflammatory cells and factors in the area (Stadelmann et al. 
1998). Vasoconstriction lasts five to ten minutes. 
3.1.3 Vasodilatation  
Vasodilatation is a widening of blood vessels that occurs about 20 minutes post-
wounding (Stadelmann et al. 1998). The main factor involved in causing vasodilatation 
is histamine. Histamine also causes blood vessels to become porous, allowing the proteins 
from the bloodstream to leak into the wound space. Increased porosity of blood vessels also 
facilitates the entry of inflammatory cells, such as leukocytes, into the wound site. 
3.1.4 Inflammation 
Polymorphonuclear neutrophils (PMNs) followed by monocytes are the first cells that 
migrate into the wound. Neutrophils appear in the wound because of their high number 
in peripheral blood. Chemoattractants, which attract leukocytes to the site of injury, are: 
fibrinopeptides, degradation products resulting from fibrin cleavage by plasmin, C5 
component of complement, leukotriene B4 released by activated neutrophils, platelet 
activating factor (PAF) released by endothelium or neutrophils and platelet factor 4 (CXCL-4) 
released from platelets (Clark 1996). 
Neutrophils at the wound site destroy contaminating bacteria by phagocytosis and 
subsequent enzymatic mechanism and by the formation of reactive oxygen species. The main 
part of neutrophils remains closed in the precipitate and dried tissue, which is in the form of 
crust separated from the wound eventually (Clark 1996). Senescent neutrophils are 
phagocytosed by macrophages (Newman et al. 1982). Wound monocytes and macrophages 
are also important for the regulation of repair progression. This was shown in animals, where 
the limited accumulation of macrophages caused delayed wound healing (Leibovich et al. 
1975). Macrophages also express the mRNA of TGF- TGF- PDGF, insulin like growth 
factor 1 (IGF-1) and these proteins play an important role in regulating wound healing 
14 
(Rappolee et al. 1988). In contrast, wound healing can take place normally without the 
presence of PMNs (de la Torre et al. 2008). 
3.1.5 Epithelization 
The epithelization of wound surface begins several hours after injury. Epithelial cells 
from non-damaged area of the skin and hair follicles are continuously covering wound. 
In addition to the migration and proliferation of keratinocytes also a phenotypic change occurs 
in the keratinocytes. Metamorphosis involves the withdrawal of intracellular filaments 
and cleavage of intercellular desmosomes (structures that connect the epithelial cells) 
and hemidesmosomes (connection between basement membrane and epidermis). The 
migrating epithelium does not terminally differentiate to cutaneous stratifying keratinocytes 
that contain keratins and filaggrin (Clark 1996). Mitogenic growth factors for epithelial cells 
include TGF-epidermal growth factor (EGF), tumor necrosis factor alpha (TNF- 
fibroblast growth factor-2 (FGF-2) also known as basic fibroblast growth factor (bFGF) and 
keratinocyte growth factor (KGF) also known as FGF-7. Keratinocytes produce collagenase-1 
(MMP-1) and plasmin during the migration and dissects fibrin eschar from the wound. Fibrin 
and fibrinogen, as a matter of fact, are anti-adhesive molecules for keratinocytes, because 
keratinocytes do not express the receptor for fibrin (V-β3 integrin). Migrating epithelium 
expresses urokinase type plasminogen activator (uPA) . uPA receptor have a role in the 
activation of plasminogen. The process of plasmin production is regulated by plasminogen 
activator inhibitor (PAI) (Hebda et al. 2004). After the completion of migration, the contact 
inhibition of proliferation occurs, the laminin is synthesized and the basement membrane is 
reconstructed. Laminin inhibits keratinocyte migration (Clark et al. 1985), whereas 
fibronectin and type I and type IV collagens promote keratinocyte migration (Woodley et al. 
1988).  
3.1.6 Formation of granulation tissue, fibroplasia and angiogenesis 
New granulation tissue begins to occur about 2 to 4 days after the injury. In addition 
to fibroblasts it contains also new capillaries, macrophages and loose connective tissue. 
Growth factors, cytokines with significant mitogenic activity, are needed to support the 
formation of the granulation tissue (Midwood et al. 2004). The source of growth factors are 
activated platelets, monocytes, but also activated parenchymal cells. 
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3.1.6.1 Fibroplasia 
The process of formation of wound connective tissue, which serves as a scaffold for 
the cells, is called fibroplasia. The sources of connective tissue in the wound are fibroblasts. 
Fibroblasts begin to deposit fibronectin, type III collagen, type I collagen (Grinnell et al. 
1981), glycosaminoglycans and proteoglycans due to presence of factors produced by 
macrophages (de la Torre et al. 2008). Type III collagen and type I collagen synthesis is 
induced by TGF- (Roberts et al. 1986). In addition to macrophages also fibroblasts are 
a source of TGF- PDGF, bFGF, KGF and IGF-1 (Clark et al. 1995; de la Torre et al. 2008). 
Also interleukin-4 was described as another inducer of type III collagen and type I collagen 
synthesis (Postlethwaite et al. 1992). In vitro, the formation of collagen is suppressed by 
collagen matrix in fibroblasts, but fibrin has little effect on suppression of collagen formation 
(Clark, Nielsen et al. 1995).  
Fibroblasts also assemble collagen molecules into fibers, which are cross-linked and 
organized into bundles. Collagen is gradually becoming a major component of acute wound 
connective tissue, with net production continuing for the next 6 weeks. The increasing content 
of wound collagen correlates with increasing tensile strength (de la Torre et al. 2008). 
3.1.6.2 Angiogenesis 
Angiogenesis during the wound repair is a formation of new blood vessels as 
a response to injury. Angiogenesis is required to establish an adequate flow of nutrients and 
oxygen to the growing tissues. Angiogenesis involves a series of sequential steps controlled 
by growth factors, cytokines and also by the extracellular matrix (ECM) components. The 
principal cells that are involved in this process are microvascular endothelial cells. After the 
enzymatic degradation of the basement membrane, chemotactic and mitogenic factors trigger 
migration, extension, arrangement and proliferation of endothelial cells. Thus new capillary 
sprouts are formed (Tomanek et al. 2000; Martin et al. 2003). According to the recent 
discoveries also the endothelial progenitor cells are essential in the vasculogenesis and wound 
healing, but their circulating and wound level numbers are decreased in diabetes (Gallagher et 
al. 2007).  
3.1.7 Contraction 
A large part of the wound fibroblasts are transforming into myofibroblasts containing 
alpha smooth muscle actin and are capable of contraction. Myofibroblasts contract due 
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to influence of TGF- and PDGF after they form links between themselves and the ECM 
(Clark 1996). The contraction of myofibroblasts is also mediated by prostaglandin F1 (PGF-
1), 5-hydroxytryptamine, angiotensin, vasopressin, bradykinins, epinephrine, and 
norepinephrine (Li et al. 2007). The subject of the wound contraction is thoroughly reviewed 
in the article by Grinnel, 1994.(Grinnell 1994) 
3.1.8 Wound tissue remodeling 
The tissue remodeling means temporary or permanent changes in tissue architecture, 
which includes cleavage of barriers such as basement membrane, basal lamina and interstitial 
stroma. The remodeling is important during the inflammatory and granulation phase, as well 
as after the closure of the wound. A typical manifestation of tissue remodeling involves a high 
production of extracellular proteinases by cells. ECM is organized into complex structures, 
each composed of various types of collagen, glycoproteins such as fibronectin, laminin, 
elastin, glycosaminoglycans (GAGs) and proteoglycans. Since these ECM components have 
different requirements for the enzymatic cleavage, remodeling involves interplay between 
several enzymes. Proteinases that degrade ECM are divided into three main groups: 1. serine 
proteinases, 2. matrix metalloproteinases (also metalloproteases, metallopeptidases) and 3. 
cysteine proteinases (cathepsins) (Li et al. 2007). 
Furthermore, endoglycosidases and exoglycosidases selectively degrade GAG 
component of proteoglycans. Previous reports have shown that serine proteinases and 
metalloproteinases are the most important during the tissue remodeling (Mignatti et al. 1996). 
Healthy human skin contains approximately 80% of type I collagen and 10% of type III 
within the total collagen. However, in early phases of repair, type III collagen is synthesized 
in higher quantities into the granulation tissue. The maximal secretion is reached at 5-7 days 
after trauma. Only during later stages of healing and during scar maturation the proportion of 
type III is lowered and the proportion of type I is increased. The character of scars gradually 
resembles that of the original skin. The tensile strength increases as the proportion of type 
I collagen increases and reaches finally approximately 70% of the original value in intact skin. 
The number of capillaries and fibroblasts decrease over time in the scar (Li et al. 2007). 
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3.2 Diabetes mellitus 
Diabetes mellitus is a chronic disease that manifests as a disturbance of glucose 
metabolism. There are two basic types according to the causes – type 1 diabetes mellitus 
(DM1) and type 2 diabetes mellitus (DM2) (Holeček 2006). 
3.2.1 Type 1 diabetes mellitus 
Type 1 diabetes mellitus is a disease characterized by the damage of pancreatic β-cells, 
which leads to lack of insulin. Today, DM1 is divided into two subgroups. Type A DM1 – the 
antibodies against pancreatic islets are present, which leads to the destruction of β-cells. 
It is an autoimmune mediated form. Type B DM1 is a severe insulin deficiency in the absence 
of autoimmune response. The autoimmune form may be caused by several factors: 
environmental factors, viral infections, genetic factors, low immunity of β-cells to the 
destruction (Rybka 2007). 
3.2.2 Type 2 diabetes mellitus 
Type 2 diabetes mellitus is the most common metabolic disease characterized 
by a relative insulin deficiency (absolute insulin levels are often increased). DM2 is 
characterized by a combination of tissue insulin resistance and impaired thus and insufficient 
insulin secretion. This leads to an insufficient body glucose utilization resulting in 
hyperglycemia. The quantitative contribution of both disturbances may be different. It is not 
clear, which deviation plays a primary role in disease development, but a prerequisite for the 
DM2 is the presence of both disturbances (Holeček 2006; Rybka 2007). Unfortunately, DM is 
a medical problem with increasing importance: 246 million adults worldwide were suffering 
from DM in 2007 and this number is expected to increase to 380 million in 2025 (Gan 2007).   
3.2.2.1 Etiology, progress and clinical symptoms of DM2 
The emergence of DM2 is connected to both genetic factors and exogenous factors. 
The most common exogenous factors include lack of physical activity, obesity, poor diet 
and smoking. One of the main causes of insulin action failure in target tissues is the insulin 
resistance. It is a condition where the organs and tissues are not able to respond adequately 
to insulin. The cause lies in the failure of insulin receptors and post-receptor processes. Due 
to insulin resistance, the demand for insulin secretion is increased. However, the β-cells 
are unable to produce insulin in the necessary extent. Failure of glucose homeostasis follows 
and the development of DM2 progresses (Rybka 2007). The most common manifestation 
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of diabetes occurs at the age of 40 to 50 years, but it may progress hidden for a long time. The 
main symptom is hyperglycemia. Other clinical signs also include polyuria (frequent 
urination), polydipsia (excessive thirst), weight loss, weakness, severe fatigue, pain, cramps, 
blurred vision (Rybka 2007) or dyslipidemia (Holeček 2006). 
3.2.2.2 Obesity and type II diabetes mellitus 
Obesity is a disease characterized by increased accumulation of adipose tissue. It 
brings many complications in diabetic patients. The main reason for the development of 
obesity is an excessive intake and insufficient energy expenditure. Genetic factors also play 
an important role. The number of obese diabetic patients is increasing every year. Up to 80 - 
90% of patients with DM2 also suffer from overweight or obesity. Every kilogram of 
overweight increases the possibility of diabetes development by 9% on average (Rybka 2007). 
The presence of obesity affects insulin resistance, which leads to an increase in insulin 
secretion.  
Adipose tissue serves as a reservoir of energy with thermoregulatory function, but it 
produces a number of proteins. These proteins, called adipokines, have effect on insulin 
sensitivity. Adipokines include interleukin-6 (IL-6), tumor necrosis factor alpha (TNF), 
leptin and others (Škrha 2005). 
3.2.2.3 Complications of diabetes 
Diabetes is a serious disease especially due to complications it causes. Changes occur 
in metabolic pathways of carbohydrates, lipids and proteins in the course of diabetes 
progression. The most common complications include cardiovascular disease, atherosclerosis, 
impaired vision, diabetic nephropathy, liver disease, diabetic neuropathy, diabetic coma, 
hypoglycemia and impaired wound healing (e.g. diabetic foot ulcerations). At the molecular 
level, non-enzymatic glycation of proteins, increased synthesis of polyols and increased 
synthesis of amino sugars is taking place (Holeček 2006; Rybka 2007). 
3.2.3 Wound healing in diabetic patients 
The diabetic defects are difficult to treat and often lead to significant patient 
discomfort or even to limb amputation. The pathogenesis of a diabetic wound is complicated. 
The formation of wounds is connected with peripheral artery disease (PAD), where blood 
flow is decreased (Brem et al. 2007), chronic venous insufficiency (CVI), where the return of 
blood to heart is impaired, neuropathies with the loss of sensibility (Piaggesi 2004), 
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microangiopathies, macroangiopathies and impaired ability to fight infection. According to 
recent research, impaired repair is also due to the presence of advanced glycosylation end 
products (Ahmed 2005) or abundant matrix metalloproteinase expression (Armstrong et al. 
2002; Rayment et al. 2008). Approximately 4 - 10% of patients with diabetes suffer from 
diabetic foot ulcers and diabetic patients often require surgery that may cause the formation of 
chronic wounds. Impaired wound repair is connected to increased morbidity and mortality 
(Bakker 1999).  
3.2.4 Local factors  
So far, several molecular factors were shown to contribute to wound healing 
deficiencies. They include impaired growth factors production (Brem et al. 2007) or their 
premature degradation by proteinases. The presence of diabetes can also cause unfavorable 
proteolytic wound environment due to increased production of several matrix 
metalloproteinases (MMP) (Burrow et al. 2007) along with lowered levels of tissue inhibitors 
of MMPs (TIMP) (Lobmann et al. 2002). The expression of IGF-1 is lowered in diabetic 
wounds (Blakytny et al. 2000).  
3.2.5 Cellular factors  
Cellular factors of impaired repair include impaired keratinocyte, fibroblast 
and macrophage function, as well as aberrant angiogenic response and endothelial 
dysfunction (Laing et al. 2007). 
Nonetheless, the exact cellular and molecular mechanisms underlying the pathogenesis 
of this complication are not fully understood. One way to understand impaired wound healing 
during DM is to study wound repair in animals. Investigators need a variety of well described 
models to choose from in order to closely mimic the issue they are planning to study. 
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3.3 Models of wound repair on experimental animals 
From an ethical and humane point of view it is very difficult or even impossible 
in standardized conditions to study experimental wound healing and to compare different 
treatments in humans. Therefore, scientists use experimental animals. The advantage of using 
rodents is the possibility to monitor the healing process during a shorter time than in humans 
(Cross et al. 1995) and to quantify healing in a reproducible way and in a controlled 
environment (Davidson 2001). Although using animal models is below the perfect picture of 
wound healing in humans, animal models remain an important element in developing new 
strategies for rational wound therapy (Davidson 2001). 
Practical issues such as price, availability and the possibility of feeding affect the 
choice of model. The most commonly used animal is the rat and mouse. Dozens of work are 
published each year describing the wounds studied in these organisms. Only a small number 
of scientists study the problem using large animals such as pigs even though they 
physiologically better mimic human healing (Davidson 2001). 
3.3.1 Basic types of experimental wounds 
The scheme in Fig. 2 illustrates the basic cutaneous wound models and relative 
proportions of various components of the wound site. In the incisional, excisional and burn 
models the epidermis and the basement membrane are disrupted, and all wounds except burns 
fill with a provisional matrix composed of fibrin, fibronectin, and other plasma-derived 
components. The dead space model segregates the wound space from surrounding tissue with 
a barrier that becomes encapsulated. As healing progresses, the wound dimensions may be 
reduced, epithelialization proceeds from the margins and residual epidermal appendages 
and the provisional matrix is replaced by granulation tissue that eventually transforms into 
scar (Davidson 2001). 
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Fig. 2 : Basic types of cutaneous experimental wounds according to Davidson, 2001, Rudas 1960, 
Galiano 2004 and their mode of healing. Red – provisional matrix, orange – epidermis, brown – basal 
membrane, yellow – granulation tissue, black – crust/necrotic tissue, grey – the walls of dead space 
model, blue – the ring being attached with a suture threads over or in the wound. 
 
3.3.1.1 Incisional wounds 
Cutting of the skin with a sharp blade results in rapid disruption of tissue integrity with 
minimal collateral damage (Fig. 2). The size of the gap in the incision will depend on 
a number of factors, including the amount of subcutaneous fat, the tensional forces on the 
wound site, the orientation of the incision and the species. The skin of loose-skinned animals, 
such as rodents, can slide and retract over subcutaneous fascia to produce initially a large gap, 
while the skin of the pig or man is firmly attached to underlying structures and opens little 
(Davidson 2001).  
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Primarily closed wounds are closed by mechanical means and heal rapidly with minimal scar 
tissue formation. Whether bandaged, sutured, stapled or clipped, the principle is always to 
reduce the tissue gap to a minimum to allow rapid and efficient bridging of the wounded 
edges by granulation tissue and new epithelium. This type of wound is suitable for 
biomechanical analysis of wound strength. It is less adequate for histological assessment, 
tissue biochemistry or epithelialization analysis because of the limited volume/area of wound 
repair activity. Wound healed by secondary closure are the incisions that are left open and are 
also said to heal by secondary intention. In this process, a much more extensive fibrin clot in 
the wound void eventually gives way to ample granulation tissue and a gap that is eventually 
bridged by epithelialization. In loose-skinned animals, wound closure is facilitated by the 
contraction of the margins to approximate the edges. Nevertheless, these wounds begin with 
several millimeters of gap and usually resolve with several tens of microns of scar tissue 
(Davidson 2001).  
3.3.1.2 Excisional wounds  
Excisional wounds involve the removal of a significant volume of the target tissue 
and the filling of the void created allows more material to be collected for determining 
biochemical and histological parameters in comparison to incisional wounds (Fig. 2). The 
excision site can be biopsied to obtain cells, tissue, RNA, exudates and histological specimens 
that have much more ample cross-sectional area and volume in comparison to incisions. 
Excisional wounds can be covered with occlusive dressings, which retain the exudate (wound 
fluid) that may be used to assess the content of various soluble factors in the wound 
environment, such as nutrients, proteinases, cytokines and tissue degradation products 
(Davidson 2001). 
3.3.1.3 Dead space models  
Dead space models are artificial, porous implants, which are used to study tissue 
formation and the effects of substances on the wound (Fig. 2). Some of the commonly used 
materials include polyvinyl alcohol (PVA) sponges, steel wire mesh cylinders, expanded 
polytetrafluoroethylene (ePTFE) and the cellulose sponge. Each dead space model has its own 
limitations based on its material's composition and implantation methods. The steel wire mesh 
cylinder model has a lag phase of infiltration after implantation and requires a long amount 
of time before granulation tissue formation begins. Later stages of wound healing are best 
analyzed using the ePTFE model. A cellulose sponge inside a silicon tube model is typically 
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used for studying human surgery wounds and wound fluid. The PVA sponge is limited to 
acute studies because with time it induces foreign body response, which causes a giant cell 
reaction in the animal. Unlike other materials, PVA sponges are easy to insert and remove, 
made of inert and non-biodegradable materials and yet are soft enough to be sectioned for 
histological analysis. In wound healing, the PVA sponge is very useful for analyzing 
granulation tissue formation, collagen deposition, wound fluid composition, and the effects of 
substances on the healing process (Deskins et al. 2012). 
3.3.1.4 Partial-thickness (split-thickness) excisional wounds   
The partial-thickness (split-thickness) injury involves the use of a sharp bladed device 
that is designed to cut parallel to the skin surface at a defined depth. In practice, a dermatome 
is usually used to shave off a 100 to 1500 µm thick layer of the epidermis and upper dermis in 
one or more passes. The term "split" refers to the fact that a substantial amount of dermis, 
mostly reticular, is left behind and, more importantly, the bases of most epidermal appendages 
(sebaceous and sweat glands, hair follicles) remain intact. Thus epithelialization is rapid 
and occurs not only from the wound margin but from epidermal appendages as well. 
Regeneration of hair follicles is dependent on the depth of excision, since progenitor cells 
reside in the shaft, not in the bulb at the base of the follicle. This type of lesion is difficult to 
generate in the mouse, because its skin is quite thin. The epidermis is only about 50 µm thick 
and the dermis is less than 1 mm. Many domestic animals are unsuitable for the model 
because of the extremely high hair density, which increases the rate of epithelialization. 
Hairless strains offer an advantage. This model is useful for determining rates of 
epithelialization and at least in the pig is a good approximation of the behavior of human graft 
donor sites. The rapid healing rate in healthy animals may make it more difficult to determine 
clear differences among treatment groups. In either case the epithelialization is not 
continuous. Extravasation of lymph and blood occurs in this type of lesion, and a typical 
eschar composed of fibrin clot and granulocytes will accumulate over the site (Davidson 
2001). 
3.3.1.5 Full-thickness wound excisional wounds 
This model involves the complete removal of the epidermis and dermis to the depth 
of fascial planes or subcutaneous fat. In the loose-skinned species, the thin musculature 
of the panniculus carnosus, which firmly adheres to the base of the dermis, is usually excised 
as well. Healing occurs from the margins and the base of the wound by the formation 
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of a fibrin clot that is invaded by granulation tissue and by the migration of an epidermal 
tongue along the interface between granulation tissue and clot (eschar). Biopsy punch, scalpel, 
scissors and dermatome (set to cut very deeply or making several successive passes) are used 
to generate this type of lesion in a standardized fashion. The laser, if controlled precisely, can 
produce a type of excision with little bleeding and the wound margins will still contain a zone 
of coagulation necrosis. The actual wound depth is very dependent on species; the mouse has 
the thinnest skin, while the pig and other large domestic animals have a dermis that is as thick 
as or thicker than humans. Bleeding and fluid loss are more extensive in the excisional model 
and there is greater susceptibility to infection. Wound dressings may be required to obtain 
predictable healing. This model offers the advantages of significant wound volume, 
involvement of all dermal components, epithelialization only from the wound margins and the 
ability to analyze chemistry, histology and cell populations in the wound site. Healing rates 
are often monitored on the basis of total excisional volume or area filled with granulation 
tissue (neodermis), extent of epithelialization, histological organization of connective tissue, 
angiogenesis and biochemical content of collagen or proteoglycans (Davidson 2001). 
3.3.1.6 Splinting – permanent wound 
In full-thickness excision, the mechanical structure of the dermis is completely 
disrupted and various forces in the surrounding dermis and the wound site can reduce the 
dimensions of the wound without actually filling the site with new tissue. Wound closure can 
be counteracted by physical splinting of the wound with retaining rings (Rudas 1960), 
biopolymer (e.g. collagen) plugs or other mechanical devices (Davidson 2001), thus creating 
permanent granulating wound (Fig. 2). 
3.3.1.7 Splinting – wound with limited contraction. 
Rodent and other loose skinned animals are known to contract their wound rapidly. 
Thus retaining rings attached on surface were introduced to limit the contraction and thus to 
replicate partially human physiology of wound repair (Fig. 2). Splinted wounds have an 
increased amount of granulation but the rate of epithelization is not affected (Galiano et al. 
2004). The ring is usually made of silicone (Michaels et al. 2007).  
3.3.2 The most frequently used models 
In a review article by Dorset-Martin it can be found that 38% of studies used the 
incision wound model and 38% used the excision wound model. The most common location 
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of wound was on the back of animals due to practical reasons (78%) (Dorsett-Martin 2004). 
Other parameters, that may influence the course of the experiment, are animal strain, age, sex, 
wound size, wound bandages, use of anesthesia and analgesia (Dorsett-Martin 2004). Further 
information about different wound models can be found in the reviews by (Davidson 1998; 
Davidson 2001; Birch et al. 2005). 
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3.4 Models of animal diabetes 
In the beginning it must be acknowledged that diabetes mellitus is a complex illness 
and no animal model is fully descriptive. Animal diabetes models can be divided principally 
into three groups: surgically induced diabetes, chemically induced diabetes and genetically 
induced diabetes (Grinnell 1984; Greenhalgh et al. 1990; Greenway et al. 1999). 
3.4.1 Surgically induced diabetes mellitus 
Surgical removal of the pancreas induces diabetes in dogs and this model has been 
intensively used in early 20th century. The experiments have led to the discovery of insulin 
(Engerman et al. 1982). At present, this model is no longer used (Greenhalgh 2003). 
3.4.2 Chemically induced diabetes mellitus  
Alloxan and streptozotocine attack beta cells in the islets of Langerhans and induce 
insulin-dependent diabetes mellitus (type I). The treated rats rapidly achieve the high 
hypoinsulinemia and hyperglycemia (Rerup 1970). It is possible to induce diabetes in rats, 
mice, hamsters, dogs and monkeys in this way. Although streptozotocine and alloxan are 
specific for beta cells, the moderate damage of other organs such as kidneys, liver and 
pancreas can occur. After the administration, the animals gain weight significantly less than 
control animals (Greenhalgh 2003). The induction of diabetes by this method is simple. 
Streptozotocine can be administered in one dose (240 mg/kg in mice or 45 mg/kg in rats) or 
the treatment can be distributed at lower doses for several days (Grodsky et al. 1982). 
3.4.3 Genetically dependent diabetes mellitus 
Like in humans also in certain animal species some individuals have genetic 
predispositions to develop diabetes. Genetic models can be divided into two subgroups: 
insulin-dependent models and insulin-resistant models. Furthermore, these models can be 
distinguished by the presence of the obesity. In most cases the insulin resistance is associated 
with the obesity (Greenhalgh 2003). 
3.4.3.1 Models of spontaneous insulin dependent diabetes mellitus 
There are several species of animals that spontaneously develop insulin-dependent 
diabetes mellitus (IDDM). Diabetes develops as a result of the auto-destruction of beta cells 
and consequent decrease in insulin production. NOD mice, BB Wistar rats, Chinese or South 
African hamsters, Yucatan mini-pigs, and some strains of guinea pigs, dogs and primates 
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are examples of genetically dependent IDDM. Only limited numbers of wound healing 
studies have been conducted on these animals. This was possibly due to better availability of 
chemically induced models of diabetes, and also due to the fact that the majority of patients, 
who have problems with wound healing have an insulin resistant DM. Studies on these 
models discovered abnormalities in tissue repair (Greenhalgh 2003).  
3.4.3.2 Models of spontaneous non-insulin dependent diabetes mellitus 
There exist several animal models with NIDDM. Models are summarized in Tab. 1. 
The majority of models are based on the mutation of leptin or leptin receptor and posses obese 
phenotype.  
Name of strain/species 
Gene 
symbol 
Mutation heredity obesity 
Mouse  
Obese ob/ob mouse Ob leptin autos. recessive obese 
Diabetic db /db mouse Db leptin receptor autos. recessive obese 
Yellow (Agouti) mouse A agouti sig.peptide autos. dominant obese 
Fat mouse Fat/cpe Carboxypeptidase E autos. recessive obese 
Tubby mouse Tub Tubby protein autos. recessive obese 
Adipose mouse Ad ? autos. dominant obese 
New Zealand mouse (NZO) - - polygenic obese 
Japanese KK mouse - - polygenic obese 
TallyHO/JnJ mouse (male) - - polygenic obese 
Rats  
Fatty (Zucker, ZDF) Fa leptin autos. recessive obese 
Goto-Kakizaki - - polygenic 
non-
obese 
JCR:LA-cp Fa leptin receptor autos. recessive obese 
SHROB(Koletsky) Fa leptin receptor autos. recessive obese 
Cohen diabetic - - - 
non-
obese 
Djungar hamser - - polygenic obese 
Rhesus monkey 
(Macaca mulatta) 
- - polygenic obese 
Ossabaw pigs - - polygenic obese 
Tab. 1: Animal models with NIDDM. The table is based on information in (Coleman et al. 1990; 
Naggert et al. 1995; Greenhalgh 2003; Shafrir 2007; Buck et al. 2011). 
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Further detailed information about various models of diabetes were described in the book: 
Animal Models of Diabetes: Frontiers in Research (Shafrir 2007). 
3.5 Advantage and disadvantages of using streptozotocine and ZDF rat 
models 
Streptozotocine induced DM is the easily accessible model of DM1. Our previous 
research on wound healing showed that at higher doses it is difficult to distinguish which 
is the effect of DM (elevated blood sugar) and what is the "added" toxic effects of 
streptozotocine (unpublished data). Epidemiologically the DM2 is the greater issue (90% of 
the total number of diabetic patients) than DM1. It is therefore preferable to use the ZDF 
model compared with streptozotocine model. However, the disadvantage of ZDF model is 
poorer availability (price, a limited number of animals). Laboratory mice have a disadvantage 
compared to rats that mice are smaller and it is not possible to create larger wounds, which are 
easier to observe and provide more material for analysis of repaired tissue. 
3.6 Zucker Diabetic Fatty rat 
The obese male ZDF rat has been an important model for studying the mechanism 
of onset and treatment of type 2 diabetes (Finegood et al. 2001; Leonard et al. 2005; Peterson 
2007), thus we have anticipated that obese ZDF rat could be a suitable model to mimic certain 
aspects that are present in diabetic patients suffering from complicated wounds. The ZDF rat 
is an inbred strain and rats with fa/fa genotype develop a genetically dependent obesity 
and subsequently diabetes due to a point missense mutation in the extracellular domain 
of the leptin receptor (Peterson 2007). Lean ZDF animals, with fa/+ or +/+ genotype do not 
develop obesity or diabetes, and serve as controls. Leptin is an adipokine and regulator of 
satiety. Leptin system also influences the metabolism of fatty acids.  Although in ZDF rats the 
monogenic genetic defect causes obesity, it is not a common cause of human obesity 
(Peterson 2007). Nonetheless the mutation causes the polyphagia in ZDF rats and similarly in 
humans, overeating is also one of the most important causalities of obesity. ZDF rats are 
characterized by non-insulin dependent DM accompanied by hyperglycemia, neuropathies, 
nephropathies, insulin resistance, mild hypertension, hypertriglyceridemia, 
hypercholesterolemia (Lee et al. 2000), polyuria, polydipsia (Peterson et al. 1990) and 
microvascular damage (Danis et al. 1993). Hyperglycemia starts to develop between 
the seventh and twelfth week of age, and is preceded by obesity and insulin resistance 
(Finegood et al. 2001). Animals gradually evolve from hyperinsulin-euglycemic state to 
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hyperglycemic state with relative insulin deficiency (Finegood et al. 2001; Leonard et al. 
2005) and the development of DM is connected with pancreatic beta cells dysfunction 
(Finegood et al. 2001). Whereas in ZDF rats DM starts to develop at an early age, in humans, 
the manifestation of type II diabetes is observed usually after the age of 40 or later. The main 
contributory factors to the development of hyperglycemia in people with type 2 diabetes are 
insulin resistance and beta cells dysfunction including defects in insulin secretion, proinsulin 
conversion and amyloid deposition in the islets of Langerhans (Kahn 2000; Finegood et al. 
2001). Pathogenesis in ZDF rats is mediated through free fatty acid-induced suppression of 
insulin that is mediated through NO induction (Shimabukuro et al. 1997). Hyperglycemia can 
be prevented by NO inhibitors (Shimabukuro et al. 1997). The progression of diabetes is 
influenced by animal feeding, mainly in females. The high content of saturated fatty acids 
supports the progression of hyperglycemia (Corsetti et al. 2000). In healthy animals, when the 
diet with high content of fats is indigested, the de-novo lipogenesis is suppressed, however 
this mechanism is impaired in obese ZDF rats (Lee et al. 2000; Bassilian et al. 2002).  
The influence of DM on the repair of tympanic perforation in ZDF rats was studied. 
It was found that the healing of this type of defect is impaired in diabetic animals (Vrabec 
1998). In spite of the usefulness of obese ZDF rats as a model for studying experimental type 
II DM and metabolic syndrome, an extensive characterization of skin wound repair has not 




Hyaluronan (HA), also called hyaluronic acid or hyaluronate in salt form, has been 
purified in 1934 and its chemical structure was resolved in 1954. Biochemically, HA is 
a linear polymer of glucuronic acid and N-acetylglucosamine and it is associated with many 
aspects of biology. HA plays an important role in maintaining the shape and form of the body, 
fills the space by organizing and modifying the extracellular matrix (ECM). HA has the 
ability to regulate proliferation and migration responses of cells, to interact with different 
surface receptors, and has the ability to penetrate the intracellular space of cells and thus 
affect cell function. It is generally accepted that HA is linked to the process of tissue repair 
(Chen et al. 1999; Jiang et al. 2007). The role of hyaluronan in wound healing is not yet fully 
explained, it appears problematic that some work has been investigating hyaluronan per se, 
but has not specified its molecular weight and other properties such as its purity and the 
source.  
3.7.1 Role of hyaluronan in biological processes of cutaneous wound repair 
HA plays an important role in tissue regeneration and healing process of skin wounds. 
As early as in the coagulation stage, during the development of blood clots, HA is integrated 
into a provisional fibrin matrix and the level of HA in the matrix gradually increases (Weigel 
et al. 1986). Synthesis of HA increases immediately after injury in place of injury of tissue 
and remains elevated in inflammatory and early granulation/epithelization phase (Brown 
2004). HA synthesis slows down in later granulation phase and accumulated HA is 
depolymerised by hyaluronidase into smaller fragments (Weigel et al. 1988; Chen et al. 
1999). Hyaluronan level gradually decreases and is being replaced by sulphated 
proteoglycans, presumably by decorin, biglycan and versican (Gallo et al. 1996). 
3.7.2 Role and biological properties of high-molecular weight hyaluronan 
HA in the ECM controls the retention of water – it maintains the hydrophilic 
environment, controls ion and molecular diffusion, and provides three-dimensional network 
(Chen et al. 1999). The function of HA is also associated with the cell adhesion (Miyake et al. 
1990). The high molecular hyaluronan reduces fibrotic healing, reduces collagen deposition 
and fibrilogenesis (Tolg et al. 2004). It has antioxidant properties to PMN-ROS (reactive 




). By the effect of radicals, HA is cleaved into 
smaller fragments (Moseley et al. 2003). It facilitates the migration of keratinocytes and 
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fibroblasts into the wound by receptor RHAMM (receptor for hyaluronan-mediated motility) 
and CD44 (Brown 2004; Tolg et al. 2004). Hyaluronan can inhibit capillary formation 
(Feinberg et al. 1983). 
Weigel and co-authors proposed a model for the role of HA in the early stages of 
wound healing. This model is based on the formation of fibrin-HA complex, which attracts 
immune cells into the wound. This matrix is further modified – degraded by entering cells that 
produce hyaluronidase and plasminogen activator. Degradation products of HA and fibrin are 
considered to be important regulatory molecules that control cellular functions such as 
inflammatory response and induction of angiogenesis (Weigel et al. 1986; Weigel et al. 1988). 
High molecular hyaluronan has been associated with cell proliferation. Several studies have 
shown that hyaluronan synthesis is linked with the proliferative state of cells. It is proposed 
that hyaluronan is not directly responsible for mitogenic activity, but creates a hydrated 
environment in the extracellular space and thereby facilitates separation of cells (Brown 
2004). Under certain conditions, it prevents cell growth, while low molecular weight 
hyaluronan fragments are associated with cell growth and metastasis (Day et al. 2004). It can 
suppress neutrophil functions such as the reduction adherence and reduce the chemotactic 
response and thus to control and moderate inflammatory response (Gallo et al. 1996). It can 
stabilize the granulation tissue (Brown 2004). 
3.7.3 Role of low molecular weight hyaluronan and oligosaccharides in wound repair 
After the injury, low molecular weight hyaluronan fragments accumulate in the wound 
(Noble 2002). They play an important role in the inflammation by affecting macrophage 
functions (McKee et al. 1996; Noble et al. 1996). HA fragments activate inflammatory genes 
in macrophages and dendritic cells (Noble 2002). They play an important role in 
angiogenesis: angiogenesis is induced by low molecular weight hyaluronan (LMWHA) (West 
et al. 1985) and collagen I and VIII is induced in bovine aortic endothelial cells (Rooney et al. 
1993). LMWHA acts by preventing drug-induced apoptosis; it induces proliferation of 
various transformed and untransformed cells (Day et al. 2004). 
 
3.7.4 Accumulation and synthesis of hyaluronan in the skin 
Hyaluronan in the skin is synthesized and secreted continuously by fibroblasts 
and keratinocytes. Normal concentration in the dermis is 0.2 to 0.5 g/kg (0.02 - 0.05%) within 
2 – 5 MDa, 0.1 g/kg in the epidermis and 2.5 g/kg (0.25%) in epidermal extracellular matrix 
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(Lepperdinger et al. 2004). During aging, its concentration in the skin decreases. At the age 
of 60 years there is a 50% decrease of HA and at the age of 75 years up to 77% decrease. 
In addition, there is an increasing proportion of de-acetylated HA with the age (Longas 2004). 
The reduced content and reduced synthesis may also partially participate in the fact that 
healing is impaired in the elderly. Hyaluronan is synthesized by the enzymes hyaluronan 
synthase 1 and hyaluronan synthase 3 (HAS-1 and HAS-3) with molecular weights ranging 
from 0.2 to 2 MDa, and also by HAS-2 with molecular weight > 2 MDa (Weigel 2004). After 
an injury to the epidermidis HAS-2 and HAS-3 are strongly induced and thus HA probably 
plays an important role in the proper course of epidermal wound repair (Tammi et al. 2005). 
3.7.5 Role of hyaluronan receptors during wound repair 
There are many receptors and binding proteins (hyaladherins) for HA. These are 
CD44, RHAMM (receptor for hyaluronan-mediated motility, CD168), TLR-4 (Toll-like 
receptor-4), Layilin, LYVE-1 (Lymphatic vessel endothelial hyaluronan receptor-1), HARE 
(Hyaluronan Receptor for Endocytosis), TSG-6 (tumor necrosis factor stimulated gene-6) 
(Longas 2004). The function of CD44 is the most clarified, the function of others is largely 
unknown. RHAMM and CD44 are induced during wound repair (Balazs et al. 2000; Tolg et 
al. 2004). CD44 is expressed on the surface of fibroblasts, smooth muscle cells, epithelial 
cells, neutrophils, macrophages, lymphocytes (Lepperdinger et al. 2004). HA signaling 
pathways through CD44 run through the activation of Rho-Rac1 GTPase complex leading to 
actin cytoskeleton reorganization (Fig. 3) (Lee et al. 2000). Another signal pathway is via 
activation of ErbB2-CD44, leading to proliferation signal through the MAPK (mitogen 
activated protein kinase), and activation of TK-src (src-tyrosine kinase) and transcription 
factor NF-B (nuclear factor kappa B), see Fig. 3. It was found that 20 kDa HA activates NF-
B, whereas HA > 1MDa inactivates NF-B (Lee et al. 2000). 
33 
 
Fig. 3: Hyaluronan–CD44 signaling pathways. HA–CD44 binding may activate several signaling 
cascades, leading to changes in cell proliferation and cell movement. (a) Activation of the src-family 
non-receptor tyrosine kinases may be dependent upon colocalization of CD44 and src kinases to lipid 
microdomains within the plasma membrane, src activation may result in activation of a protein kinase 
C (PKC) cascade. (b) CD44–erbB2 dimers may activate a MAP kinase cascade or alternate cascades.  
(c) NF-B may be activated through a Ras, PKC-dependent cascade. (d) Alternatively, HA–CD44 
interaction may modify local cytoskeletal assembly through activation of the small GTPases such as 
RhoA and Rac1. Taken from (Lee et al. 2000). Figure reuse in present thesis was licensed by the 
Elsevier Copyright Clearance Center.  
 
3.7.6 Interaction of hyaluronan with other ECM molecules and chemokines  
Hyaluronan interacts with fibrin (Weigel et al. 1986; Weigel et al. 1988). HA interacts 
with hyalectins, for example with versican (chondroitin sulfate proteoglycan) that is induced 
during reparative processes (Carthy et al. 2011). HA organizes collagens and extracellular 
matrix (Chen et al. 1999; Brown 2004). HA binds to the complex TSG6 IAI-(TNF-stimulated 
gene, Inter-alpha-inhibitor, proteinase inhibitor) and this complex prevents inflammatory 
damage to tissue proteinases and stabilizes the granulation tissue (Brown 2004). 
3.7.7 Hyaluronan and fetal wound healing   
Hyaluronan level is high in fetal wound and HA may play an important role in fetal 
scar-free healing. Fetal scar-free healing is characterized by faster epithelization, sterile 
environment, a reduced inflammatory response and reduced angiogenesis (Balazs et al. 2000). 
Applied HA reduced the expression of TGF which is known to occur in wounds that heal 
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in scar-like manner and TGF- is reduced to a scar-free fetal wounds (Torregrossa et al. 
1983).  
3.7.8 Clinical studies with applications of hyaluronan for supporting wound repair   
In a multicenter controlled study 50 patients with venous ulcers were treated with 
daily HA gauze pad compared with dextranomer paste for 3 weeks. In both groups the 
appearance and the size of ulcers was significantly improved. Faster and larger reduction of 
ulceration was observed in the HA treated group (Ortonne 1996). In a study of etiologically 
different ulcers of lower extremities, in which conventional therapy was compared with HA 
treatment, a significantly greater number of healed wounds was found in the HA group 
(Torregrossa et al. 1983). Improved healing was observed in a study, where HA was applied 
with glycerin to patients suffering from venous ulcers (Passarini et al. 1982). In a similar 
study (Galasso et al. 1978), there was no positive effect of HA compared to control ZnO 
paste. In clinical trials of Hyalofill (contains benzyl ester modified HA), 36 neuropathic 
diabetic patients were treated until the wound was fully covered with granulation tissue. 
Therapy was then replaced by keeping the moisture lining. 75% wounds were healed at an 
average of 10 weeks (Vazquez et al. 2003). 
3.7.9 Observation of effect of HA on wound healing in animals. 
Hyaluronan at the concentration of 2% had a positive effect on wound healing in 
alloxan-induced diabetic rats. It modified and facilitated the migration of the epithelial cells 
and their differentiation (Abatangelo et al. 1983). Closing of the wound in rats by the action 
of HA on three-dimensional matrix seeded with keratinocytes and also without keratinocytes 
is substantially improved (Hu et al. 2003 ). Further experiments with HA film in rats showed 
reduced inflammatory activity, accelerated epidermal healing. The HA film may have a strong 
activity on supporting infiltration in the early stages of healing, can accelerate the healing 
of the epidermis, and slow the formation of keratinized layer (Ren et al. 2004). The effect 
of ultrapure HA of different molecular size has been studied in comparison to the effect 
of saline solution on deep skin wounds in Chinese pigs. The tensile resistance of the wound 
was reduced by the high and medium molecular weight (MW) HA. Using laser Doppler scan 
3 days after injury, the blood perfusion in the wound was decreased in high MW HA and 
intermediate MW HA groups, but in seven days in the blood perfusion was increased in all of 
HA groups (Jia et al. 1998). In a study where collagen-HA sponge implant was engineered 
and implanted into the wounds of guinea pigs, it was found that hyaluronan caused increased 
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chemoattraction, replication of fibroblasts and collagen deposition (Doillon et al. 1986). HA 
in the collagen sponge had positive effects on wound healing in guinea pigs. Improved 
healing from the 16 days to 9 days by the action of HA was observed. Furthermore, in this 
work doubled vascularization was observed by HA treatment on day 2 to day 4 days after the 
injury, but these differences settled during the complete closure (King et al. 1991). Artificial 
skin substitute (collagen matrix without cells) soaked in 0.3% hyaluronan induced the 
ingrowth of granulation tissue and capillaries on the model of deep wounds in rats, and thus 
potentially facilitated the use of skin grafts (Murashita et al. 1996). HA modulates acute and 
chronic inflammation in rat model of arthritis and edema (Ialenti et al. 1994). HA stimulated 
B cells, which infiltrates into wounds to produce interleukin-6 and transforming growth 
factor-beta (TGF-β) through TLR-4 in a CD19-dependent manner (Iwata et al. 2009). 
3.7.10 Products for wound care based on hyaluronan 
Several wound care products contain hyaluronic acid or its salts. Ialugen plus (IBSA, 
Switzerland) contains the combination of silver sulfadiazine (1%) and sodium hyaluronate 
(0.2%) in form of cream. Company Fidia, Italy, fabricates several products for wound repair: 
Hyalosilver (sodium hyaluronate 0.2% + colloidal silver 2%), Jaloplast (Hyaluronic acid 
sodium salt 0.2%, cream), Jaloplast Plus (Hyaluronic acid sodium salt 0.2% + Silver 
sulfadiazine 1%, cream). Hyalofill (Convatec, USA) is a dry wound dressing composed 
of a HYAFF (benzyl ester of hyaluronan). Hyalofill forms a thick HA-rich gel, liberating HA 
into the wound for up to 2 to 3 days. Traumacell Biodress H-gel (Bioster, Czech Republic) 
contains 1% of sodium hyaluronate and 1% of hydrogen calcium salt of oxidized cellulose. 
Hyaluricht/Curiosin (Chemical Works of Gedeon Richter, Hungary) is marketed in the form 
of gel or solution and it contains 0.102% or 0.205% of zinc hyaluronate. Hyaluricht is the first 
drug containing zinc bound to hyaluronic acid. Zinc participates as a cofactor in more than 
70 enzymes, some of which are involved in the biochemical processes of wound healing. 
Thus, zinc hyaluronate has a complex effect on physiological wound healing, preventing 
ulcers from infection because of its antimicrobial activity against a number of bacteria. It is 
a clear sterile solution with physiological osmolality and pH 5 – 6. Hyaluricht does not affect 
the skin around ulcer and does not stick to the wound (Illes et al. 2002). Hyaluronic acid is 
a component of advanced therapy medical products produced by Fidia, Italy, such as 




Iodine has been used for many years to treat wounds as an antiseptic. As iodine is 
a strong oxidizing agent and could cause wound irritation when applied in high concentration, 
the pharmaceutical companies invested in last 60 years to the development of safe forms 
of iodine application, e.g. by using iodophors with slow release of iodine. It is active against 
many bacteria, viruses and fungi and it may also increase the healing rate (Selvaggi et al. 
2003; Cooper 2007). Polyvinyl pyrrolidone – iodine preparation in hydrogel was reported 
to improve healing by increasing wound moisture and by preventing bacterial infection. The 
epithelialization of meshed skin grafts was increased in human patients after hydrogel 
application (Vogt et al. 2006). Cadexomer iodine is a promising treatment to clear 
Staphylococcus aureus cells within biofilm from skin lesions of exudative or infectious 
wounds and to prevent wound exacerbation (Akiyama et al. 2004). Wound dressings 
containing either silver or iodine (Aquacel Ag and Iodozyme) exerted an antimicrobial effect 
against the biofilms of Pseudomonas aeruginosa and S. aureus, although the iodine dressing 
was more efficacious under the experimental conditions employed (Thorn et al. 2009). 
Epithelium of chronic venous ulcers grew faster after treatment with cadexomer iodine when 
compared to standard dressing (Ormiston et al. 1985). Besides supporting epithelialization, 
iodine preparations may influence cytokine production by macrophages (Moore et al. 1997) 
and modulate the redox environment of wounds (Schmidt et al. 1995).
 
3.9 Hyiodine 
The mixture of HA and iodine complex KI3 (Hyiodine) was used by Sobotka et al. 
(2006, 2007) to treat chronic non-healing wounds in diabetic patients. Clinical improvement 
was found in a majority of patients. Accelerated healing of chronic wounds treated with 
Hyiodine was also reported by Ajemian et al. (Ajemian et al. 2007; Brenes et al. 2011). 
Complex of HA and iodine was found to be safe and effective in healing sternal wound 
dehiscence (Brenes et al. 2011). Hyiodine is a novel preparation used for wound treatment 
that supports wound hydration. The concentration of iodine in Hyiodine is lower (0.1%) in 
comparison to Betadine (~1% of iodine). 
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4 Methods  
4.1 Animals  
4.1.1 Experiments with permanent wounds in Wistar rats 
Wistar rats (Biotest, Konárovice) weighing about 350 g and 9 – 10 weeks old were 
used. The work with animals was done according to the acknowledged project under current 
rules of “§ 11 Vyhláška č. 207/2004 Sb. (o ochraně, chovu a využití pokusných zvířat)”. The 
project was acknowledged by the Ethics Committee of Medical Faculty in Hradec Králové 
and by the Committee for Animal Protection of Ministry of Education, Youth and Sport 
of Czech Republic on 15
th
 of May 2005. The work was divided into 3 experiments with 25 
animals. Three animals were removed from the experiment due to removal of the ring 
implant. In each of 3 experiments, the animals were divided into 5 groups with n = 5 animal 
making together n = 14 – 15. In each group 0.6 ml of the solution was applied on the wound 
with a syringe. Groups were following:  
 SALINE: a control group, treated with physiological solution (Medicamenta). 
 HA11: treated with very low molecular weight (m.w.) hyaluronan with 11 kDa m.w. 
in average (1.5% solution, Contipro, filter sterilized). 
 HA1200: treated with hyaluronan with 1200 kDa m.w. in average (1.5% solution, 
Contipro, sterilized by autoclaving at 120 °C during 15 min). 
 KI3 (KI/I2): treated with dissolved Lugol’s solution (0.1% I2/0.15% KI). KI – Sigma, 
30315, puriss., Ph.Eur.; I2 – Riedel-de Haen, 03002, puriss, Ph.Eur.  
 HYIO: treated with Hyiodine (1.5% sterile autoclaved solution of 1200 kDa 
hyaluronan with addition of 0.1% I2 and 0.15% KI, Contipro Dolní Dobrouč). 
 
4.1.1.1 Experiments with contractile wounds in Wistar rats 
40 Male Wistar rats (Biotest), 9 – 10 weeks old and weighing 300 – 380 g were 
housed in individual cages and fed commercial pelleted diet ad libitum. They were maintained 
in an air-conditioned room at 22 °C. The experiments were approved by the Ethics Committee 
of the Faculty of Medicine in Hradec Králové. 
 16 rats were observed until full wound closure (2 groups, n = 8), 
 24 rats were used for the histological assessment of wound tissue (2 groups, 4 time 
intervals – 3, 7, 11, 15 days, n = 3). In desired time interval the rats were euthanized 
and the wound tissue was taken for the histological analysis.  
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Groups were following:  
 SALINE: a control group, treated with physiological solution (Medicamenta). 
 HYIO: treated with Hyiodine (1.5% sterile autoclaved solution of 1200 kDa HA with 
addition of 0.1% I2 and 0.15% KI, Contipro Dolní Dobrouč). 
 
In each group 1 ml of the solution was applied on the gauze with a syringe and then applied 
on the wound.  
4.1.2 ZDF animals and work with ZDF animals 
Male and female ZDF rats that originated from Charles River (USA) were purchased 
from Anlab (Prague, Czech Republic) in March 2006. For the purposes of experiment the 
offsprings were bred in a vivarium at the Faculty of Medicine in Hradec Králové by mating 
non-obese heterozygous (fa/+) carrier parents or by mating fa/fa males with fa/+ females. This 
resulted in approximately 25% and 50% obesity rates, respectively. During the experiments 
with wounds, the rats were housed in individual cages. All animals were fed standard 
laboratory diet ST-1 (8% kcal fat, Velaz, Lysá nad Labem, Czech Republic) until the age of 
6 – 8 weeks. Diabetes was then induced by feeding high fat diet (Peterson 2007) ad libitum: 
PURINA 5008 (17% kcal fat, IPS Supplies) was used for males and C13004 (48% kcal fat, 
Research Diets, New Brunswick, NJ, USA) was fed to females. Animals were considered to 
be diabetic when their non – fasting glucose levels reached 14 mmol/l in males and 9 mmol/l 
in females and when they possessed obese phenotype. Animals were maintained in an air –
 conditioned room at 22
o
C with an automatic light/dark cycle. The experiments were 
approved by the Ethics Committee of the Faculty of Medicine in Hradec Králové (9.1.2006) 
and by committee of Ministry of Education, Youth and Sport of Czech Republic.  
4.1.2.1 Experiments 
As ZDF animals were difficult to breed and were bred continuously in smaller 
numbers, there were many small experiments that were combined. In one experiment, animals 
with similar age and diabetic status were used. Totally 24 experiments with 2 – 12 animals in 
each experiment were done without bandage (air exposed wound) and 30 experiments with 2 
– 16 animals in each experiment were done with bandage (bandaged wound). 
For both sexes these groups were created:  
 Non – diabetic: control group – lean animals with genotype +/+ or fa/+, 




4.2.1 Purina 5008 and RD 13004 
Animals were fed high fat diet from 6 – 8 week of life. Males were fed Purina 5008 
(16% of kcal fat), (Peterson 2007). Females were fed with RD 13004 (48% kcal of fat), 
(Peterson 2007). 
4.2.2 H1 and HZ2 
Diets H1 and HZ2 were developed as a potential replacement for the C13004 in order 
to induce high hyperglycemia. Diet C13004 induced only mild levels of hyperglymia (see 
further on), and this was also confirmed by the supplier of the diet. The difference between 
H1 and HZ2 was the content of the fat. Another reason for developing an alternative diet to 
C13004 was high price and shipping costs. Tab. 2 shows the composition and nutritional 
values of H1 in comparison with C13004 and HZ2. 
C13004 composition % protein fat fiber saccharides moisture ash total 
Purina 5015 65% 18,9% 11% 2,2% 52,20% 10% 6% 100% 
maltodextrin 42 5% 0% 0% 0% 96% 4% 0% 100% 
Homilc 7-60 30% 7% 60% 0% 27% 3% 3,60% 100% 
  
       
  
total C13004   14,4% 25,2% 1,43% 46,8% 7,6% 4,98% 100% 
                  
H1 % protein fat fiber saccharides moisture ash total 
ST1 (non-granulated) 60% 24% 3,5% 3,7% 50,5% 11,8% 6,5% 100,0% 
lard (pork) 25% 0,2% 99,5% 0% 0% 0,2% 0,1% 100,0% 
cornstarch 5% 0,3% 0,05% 0,9% 90,3% 8,3% 0,1% 100,0% 
sugar (white) 10% 0% 0% 0% 100% 0% 0% 100,0% 
  
       
  
total H1   14,5% 27,0% 2,3% 44,8% 7,5% 3,9% 100% 
                  
HZ2 % protein fat fiber saccharides moisture ash total 
ST1 (non-granulated) 50% 24,00% 3,50% 3,70% 50,50% 11,80% 6,50% 100% 
lard (pork) 35% 0% 99,5% 0% 0% 10% 0% 100% 
cornstarch 5% 0% 0% 1% 91,3% 8,3% 0,1% 100% 
sugar (white) 10% 0% 0% 0% 100% 0% 0% 100% 
  
       
  
total HZ2   12,0% 36,6% 1,9% 39,8% 9,8% 3,3% 100% 
Tab. 2: Composition and nutritional values of diets C13004 (Labdiets), H1 and HZ2. Nutritional 
values of components were obtained from the component’s specification sheets or from National 
Nutrient Database for Standard Reference Release 25 (http://ndb.nal.usda.gov/) or from 
http://www.lucy.cz/energeticke-tabulky/. 
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4.3 Genotypization of ZDF animals   
ZDF animals were genotyped by using a PCR followed by a cleavage by restriction 
endonuclease MspI (Sudre et al. 2002). The method is described below. The DNA was 
obtained by using Viagen Direct PCR solution or QIAGEN DNeasy kit. The photographs of 
gels were taken by a camera Canon 300D. 
4.3.1 Materials and chemicals 
 Primers (Generi Biotech, Hradec Králové) 
sZDFfa1: 5'-CGT ATG GAA GTC ACA GAT GAT GGT AAT-3' 
sZDFfa2: 5'-CCT CTC TTA CGA TTG TAG AAT TCT CT-3' 
 Reagents for PCR (Taq polymerase Fermentas, EP0401, Vilnius, dNTP Mix 10 nM) 
 Restriction endonuclease Msp I (Fermentas, ER0541) 
 Materials for DNA extraction: Viagen Direct PCR or QIAGEN DNeasy 
 Materials for agarose electrophoresis : DNA ladder (FastRuler™ Ultra Low Range 
DNA Ladder, ready-to-use: 10, 20, 50, 100, 200 bp, Fermentas or Fermentas – 
SM1233 Ultra Low Range DNA Ladder (Biogen) 
 PCR thermocycler (Biometra) 
4.3.2 PCR amplification of gene for leptin receptor  
Master Mix (MM) was prepared for desired number of reactions according to Tab. 3. 
MM was divided by 24 µl to the PCR tubes and 1 µl of genomic DNA (approximately 100 
ng) was added to each tube.  
Chemical 
volume (µl) for one 
reaction 
volume (µl) for 10 
reactions 
10x polymerase buffer 2.5 25 
primer sZDFfa1 (10 µM) – 40 pmol 4 40 
primer sZDFfa2 (10 µM) – 40 pmol 4 40 
50x dNTP Mix (10 mM each) 0.5 5 
Taq polymerase 0.2 2 
MgCl2 (25 mM) 2.5 25 
water (suitable for PCR) 10.3 103 
Genomic DNA – 100 ng 1 10x1 
Total 25 250 
Tab. 3: Preparation of Master Mix for PCR reaction. 
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DNA was amplified in the thermocycler using temperature program for ZDF genotyping (see 
Tab. 4). The product of PCR reaction (5 µl) was analyzed on 3% agarose gel at 70 V for 1 
hour (TAE buffer) with a suitable DNA ladder. 118 bp bands were expected. 
 
95 °C – initial denaturation 2 min  
95 °C – denaturation 30 s 33 x 
64 °C – annealing 1 min 33 x 
72 °C – elongation 30 s 33 x 
72 °C – final elongation 2 min  
Tab. 4: Temperature program for genotypization of ZDF animals. 
4.3.3 Restriction cleavage of PCR product 
For each sample the mixture of 20 µl of PCR reaction solution with 1 µl of Tango 
Buffer and 1 µl MspI nuclease (30 U/µl) was prepared. After mixing and short spin the tube 
was incubated for 1 hour at 37 °C in the thermocycler. 11 µl of mixture was used for 4% 
agarose gel electrophoresis at 70 V for 1 hour and 30 min (TAE buffer), with a suitable 
ladder. 
4.3.4 Analysis of results 
Bands for the +/+ (wild type) genotype had 118 bp in size, for +/fa genotype had size 






4.4 Measurement of glycemia   
A drop of blood was collected from the tail vein. Portable glucose meter, Accu-Chek 
Go was used for glucose measurement using a drop of blood according to a procedure bellow. 
4.4.1 Materials  
 Laboratory rat 
 Blood glucose meter Accu-Chek Go (Roche) 
 Blood glucose test strips (Roche) 
 Needle (23G), syringe, gauze, Ajatin (disinfection solution) 
 Sampling container 
4.4.2 Procedure 
Rat was inserted into a sampling container and its tail was cleansed under a stream of 
warm water (about 40 °C) and wipe-dried. After the localization of the tail veins the needle 
was inserted into the tail vein at the back of the tail. Minimally 10 µl of blood was sampled by 
an outflow. A new test strip was inserted into the glucose meter and as soon as a flashing drop 
appeared on the display, the tip of the strip was inserted into a drop of blood. Once the drop 
was aspirated, the sound indicated correct sampling and the display showed the level of 
glucose in mmol/l. Excess blood on rat’s tail was removed with gauze and rinsed with a 
disinfectant solution (Ajatin). 
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4.5 Creation of a permanent wound and granulation tissue collection 
The permanent wounds (Fig. 4) were created as described by (Rudas 1960). The 
details of the procedure are described below.  
  
 
Fig. 4: The picture of permanent wound. In the upper part an implanted plastic ring without the cover 
is shown.   
4.5.1 Materials 
 Rat 
 Nembutal (pentobarbital 50 mg/ml), ether 
 Clippers 
 Pliers (bone rongeurs 19 mm) 
 Plastic rings into the wound, nylon wound cap 
 Surgical thread 
 Superglue 
4.5.2 Procedure of permanent wound induction 
The rats were anesthetized by applying a solution of Nembutal intraperitoneally at a 
dose of 1 ml per kg of rat weight. The rats were attached on the operational board (stomach 
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down) and their coat on the back was shaved with clippers. A fold of skin was made by 
gripping it in two fingers and the skin was cut out at a distance of about 6 cm from the ear 
using pliers and scissors. This procedure should create regular circular wound, approximately 
18 - 20 mm in diameter. The wound should not bleed. 4 threads were sewn into the skin about 
3 mm from the edge of wound, each at intervals of 90 degrees. Plastic ring was inserted into 
the wound.  Threads were inserted into the holes in the ring and the ring was attached 
carefully with threads at the back of the rat. The superglue was applied to the top of the ring 
and the nylon cap was stuck to the ring. The cap was attached to the ring by tying it with a 
thread. The solution was applied to influence the formation of granulation tissue by syringe 
and needle. Every day 0.6 ml of the solution was applied for seven days. Application was 
made with a syringe and a needle piercing through a nylon cap. 
4.5.3 Sampling of the granulation tissue 
The rat was put in a container to inhale the ether until the rat stopped breathing. The plastic 
ring was removed by cutting off all the threads holding it. The fibro-vascular granulation 
tissue in the size of the internal ring radius and height of about 1 - 2 mm was cut out carefully, 
using surgical curved scissors. It was important not to cause the discharge of blood to the 
tissue. The whole tissue was weighted. The half of the tissue was put to buffered 
formaldehyde for histological analysis. The rest of the tissue was cut into small pieces 
(approximately 50 mg ~ 4 x 4 x 3 mm) and inserted into: 
1. a pre-weighed micro-vial with a screw cap ( 30 - 60 mg tissue is needed for 
hydroxyproline,  
2. a tube with 0.5 ml RNA later (Qiagen) solution (about 30 mg of tissue should be 
immersed for RNA isolation). The tissue was incubated in RNA latter for 24 hours at 
4 °C in order to penetrate the sample. Then, the sample was stored at -20 °C.  
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4.6 Induction of contractile wounds, tissue sampling 
Full-thickness, 2 cm large in diameter, excisional wounds were made on the back of 
experimental animals. Procedure of wound induction, substances application and sampling are 
described below in detail.  
4.6.1 Materials and chemicals 
 laboratory rat 
 Nembutal (pentobarbital 50 mg/ml, dose 50 mg/kg) or ketamine (100 mg/ml) and 
xylasine (20 mg/ml), dose 75 and 5 mg/kg respectively, ether 
 trimming clippers 
 curved surgical scissors 
 Luer bone rongeur forceps (19mm) - pliers 
 millimeter ruler 
 Digital Camera (Canon EOS D350) 
 gauze compress, gauze (sterile), tape, elastic gauze  
 image analysis software ImageJ (available at http://rsb.info.nih.gov/ij/) 
4.6.2 Procedure 
4.6.2.1 Induction of wound 
The rats were anesthetized by applying a solution of nembutal intraperitoneally at a 
dose of 1 ml per kg rat weight or a mixture of ketamine and xylasine (3:1), 75 and 5 mg/kg, 
respectively. The blood was sampled with a glass capillary from retro orbital plexus. The rats 
were attached on the operational board (stomach down) and their coat on the back was shaved 
with clippers.  A fold of skin was made by gripping it in two fingers and the skin was cut out 
at a distance of about 6 cm from the ear using pliers and scissors. This procedure should 
create regular circular wound, approximately 18 - 20 mm in diameter. The wound should not 
bleed. The millimeter ruler was put near the wound and a picture was taken with a digital 
camera. The substances soaked in a gauze were applied on the wound. Another gauze pad was 
applied on the wound, fixed with a tape, and elastic gauze (Fig. 5). 
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Fig. 5: Picture of the treated rat with a gauze pad, gauze and tape. 
4.6.3 Application 
Every one to three days (according to plan of experiment) the treatment was applied 
and the bandage was changed.  In case of monitoring of diabetes impact on healing no 
curative treatment is applied.  
4.6.4 Sampling the tissue 
The rat was put into a container to inhale the ether until the rat stopped breathing. The 
rats were euthanized by cervical dislocation. After the removal of the bandage a picture of the 
wound with crust was taken. If possible, the crust was removed carefully and stored for 
further analysis. The picture of the wound without the crust was taken.  Fibro-vascular 
granulation tissue also with 3 mm of uninjured skin was cut out carefully, using surgical 
curved scissors. The tissue was split into two halves. The first half was put to buffered 
formaldehyde for histological analysis. The uninjured skin was cut off from the second half 
and the remaining granulation tissue was weighted. The tissue was cut into small triangular 
pieces (approximately 50 mg ~ similarly to cutting of pizza slides) and inserted into: 
1. a pre-weighed micro-vial with a screw cap (30 - 60 mg tissue was needed for 
hydroxyproline,  
2. a tube with 0.5 ml RNA later (Qiagen) solution (about 30 - 50 mg of tissue was 
immersed for RNA isolation). The tissue was incubated in RNA latter for 24 hours at 
4 °C in order to penetrate the sample. Then, the sample was stored at -20 °C.  
During the experiment, especially during first 3 days, it was important that rats were kept on 
dust-free bedding. For this purpose, filter paper or paper wood pulp was used as an absorbent. 
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4.7 Photographing wounds, wound size analysis 
4.7.1 Photographing the wound 
Photographs of wounds were taken every one to three days. If the bandage was 
applied, photographs were taken at each bandage change. When photographing the wound, a 
millimeter ruler was placed approximately 5 mm from the wound edge . Wound surface and 
ruler was in one plane. 
4.7.2 Measuring the wound 
The picture of the wound was open in ImageJ software. The image calibrated using a 
known length (2 – 4 cm):  
i)    the option straight line selection was selected; 
ii)   the line with a known distance (on ruler) was selected ;  
iii) the function  Analyze → Set Scale → Known Distance was used with the length of the 
calibration line, e.g. 3 cm - see Fig. 6;  
The scale of image in pixels/cm was automatically calculated.  
 
Fig. 6: Calibration of pictures. 
 
A border line was made around the wound using function Polygon Selection  (Fig. 7). The 
function Analyze → Measure was selected. The program calculated wound area in cm
2
 and 
showed it in a table.  The procedure was repeated with next pictures and the table with results 
was copied to MS Excel. 
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Fig. 7: Border-line selection around the wound 
 
4.8 Hydroxyproline determination 
Approximately every seventh amino acid in collagen is hydroxyproline. Other proteins 
with the exception of elastin are practically hydroxyproline-free. Hydroxyproline content was 
determined by the method of (Hurych et al. 1962). The details of the procedure are described 
below.  
4.8.1 Chemicals and materials  
 CAP 4X (citrate-acetate buffer)  1000 ml pH= 6.3, conserved with two drops of 
toluene  
 50 g citric acid.H20 p.a. (Penta, 27490 1) 
 12 ml glacial acetic acid (Lachner) 
 120 g sodium acetate.3H20 p.a. (Penta, 71193 1) 
 34 g NaOH 
 CAP 1X (citrate-acetate buffer):  250ml CAP 4x with 750 ml of distilled water 
 PCAP (propanol-citrate-acetate buffer) – 100 ml 
 30 ml propanol 
 20 ml H2O 
 50 ml CAP 4X 
 0.84% solution of chloramine-T (Sigma – Riedel-de Haen, cat.no. 31224) in PCAP   
 5% PDAB (p-dimethylaminobenzaldehyd, Sigma-Aldrich) in propanol 
 Stock solution of hydroxyproline (Sigma-Aldrich) 10000, 500 g/ml in injection water 
and 8 µg/ml in CAP 
 Thermoblock 
 UV/VIS Spectrophotometer (Helios) 
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 1,5 ml micro-tubes 
4.8.2 Procedure 
Hydrolysis of granulation tissue (GT) and dry mass determination 
An empty polypropylene sample tube with a screw cap was weighted with 0.1 mg 
accuracy.  The tube with the sample was weighted and the mass of wet GT (VGT) calculated.  
GT was dried at 80 °C in an open tube in the thermoblock until constant weight is achieved (3 
hours was usually suitable). The mass of dried granulation tissue (DGT) was calculated. % 
dry weight was calculated as a ratio of DGT/VGT. 6M HCl was added to the tube in 1:100 
ratio (to 10 mg DGT 1000 l of 6M HCl was added) and hydrolyzed for 16 hours at 105 °C in 
a thermoblock or in a dryer. The samples were centrifuged for 10 minutes at 10000x g. The 
hydrolysate was then stored in clean tubes at 4 °C. 
 
Determination of hydroxyproline from hydrolysate 
Chloramine-T, PDAB and stock solutions of hydroxyproline for the calibration curve 




S 0 - blank S 0.5 S 1 S 2 S 4 S 8 
250 µl CAP 250l  S 1 250 l S 2 250 µl  S 4 250 µl HYP 8 250 HYP 8 
 250 µl  CAP 250 µl CAP 250 µl  CAP 250 µl CAP  
Tab. 5: Dilution of hydroxyproline standards. 
 
2.5 µl of GT hydrolysate was diluted with 247.5 µl of CAP 1X.  250 µl of solution of 
chloramine-T was added and incubated for 20 minutes at room temperature. 250 µl of 3M 
HClO4 was added, mixed thoroughly and incubated for 5 minutes at room temperature. 250 µl 
of PDAB solution was added, mixed and incubated for 20 minutes at 60 °C in the 
thermoblock. After cooling down for 20 minutes at room temperature the samples were 
measured for the absorbance at 560 nm against blank. The concentration was calculated using 
the calibration curve. The absorbance of most concentrated standard was usually around 0.8. 
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4.8.3 Protein and uronic acid determination 
The crust with jelly-like exudate was extracted with 0.5 mol ⁄ L NaOH at 60 °C for 2 h 
(Simeon et al. 2000). The mixture was neutralized and ethanol was added to the final 
concentration of 80% (v ⁄ v). After centrifugation, the precipitate was redissolved in 0.5 mol ⁄ 
L NaOH and used for protein and uronic acid determinations. Protein was measured using a 
commercial protein assay (DC Protein Assay; Bio-Rad,) with bovine serum albumin (Sigma) 
as a standard. The carbazole method (Bitter et al. 1962) was used to determine uronic acid 
levels, and D-glucuronic acid (BDH Biochemicals) was used as a standard. 
4.8.4 Polyacrylamide gel electrophoresis 
Protein samples were boiled with dithiothreitol and SDS, applied to 8% acrylamide gel 
and electrophoresed. For the samples, 30 µg of rat serum or plasma proteins, 30 µg of proteins 
extracted from the crust ⁄ exudate, or 15 µg of bovine serum albumin (Sigma) were used. 
After resolution, the proteins were stained with Coomassie Blue. 
4.9 Determination of leptin, insulin, PAI-1, IL-6 and CRP in plasma 
The blood was taken from the orbital plexus into the heparinized tubes with 
a separation gel (Sarsted Microvette). Heparinized blood was centrifuged at 13000 rpm for 
5 minutes. ELISA kits for proteins/peptides determination were used according to the 
recommendation of manufacturers.   
 Mercodia Rat Insulin ELISA (10-1113-01) 
 Alpco, Salem, USA (45-IL6RT-E01.1) and Bender MedSystem rat IL6 ELISA (BMS625) 
 American Diagnostica Imunoclone Rat PAI-1 ELISA kit (601) 
 Leptin rat ELISA: Biovendor, Brno, Czech Republic (RD291001200R) 
 CRP (c-reactive protein) rat ELISA: Biovendor, Brno, Czech Republic (RH951CRP01R) 
The determinations by ELISA were done by Mgr. Tkáčová under the supervision of author of 
the present thesis. Detailed procedures and the results are a part of her diploma thesis.  
4.10 Malondialdehyde measurement using HPLC 
The measurement was done in co-operation with the Department of Pharmacology, 
Faculty of Medicine in Hradec Králové by Miloš Hroch, MSc., PhD. In short, the analysis 
was based on alkali hydrolysis (6M NaOH), de-proteination with perchloric acid (35% v/v) 
and addition of derivatization reagent (5mM dinitrophenylhydrazine in HCl). The analysis of 
51 
product was done on Agilent HPLC equipment with a UV/VIS detector on a column with 
reverse phase separation EC NUCLEOSIL 100-5 C18 (4.6x125mm). 
4.11 Histological analysis of uninjured skin  
The skin that was removed during the wound induction was used for the histological 
analysis of uninjured skin. Tissue was fixed in 10% neutral buffered formalin (4% 
formaldehyde) for several days at 4 °C and embedded in paraffin. Six µm sections were 
stained at the Department of Histology and Embryology, Faculty of Medicine in Hradec 
Králové (Jana Holerová). The tissue was stained with blue trichrome for collagen and also 
with haematoxylin and eosin.  
4.12 Histological analysis of granulation tissue  
Wound biopsies that included wound tissue and approximately 3 mm of surrounding 
uninjured skin were fixed in 10% neutral buffered formalin for several days at 4 °C and 
embedded in paraffin. Six m sections were cut at the center of the wound, perpendicularly to 
the wound surface. Tissue sections were stained with haematoxylin and eosin or with blue 
trichrome. 
4.13 Image analysis of histological sections 
For the image analysis the samples were scanned with a scanner Epson Perfection 
V700 Photo, using resolution 4800 dpi, (1890 pixel/cm). Software ImageJ (NIH) was 
calibrated with this value. Samples were analyzed for: length of epithelization tongue, fat 
content in tissue (wound, skin), granulation tissue content, and thickness of crust (wound), fat 
layer and dermis (skin) using image analysis with ImageJ.  
4.14 Processing and statistical evaluation of data 
Data were accumulated into MS Excel. Graphs were made in this program and where 
suitable, the differences between groups were evaluated using unpaired t-statistical test. 
4.15 Isolation of RNA 
A slice of granulation tissue (without surrounding intact skin, without wound crust) 
was homogenized in the lysis buffer (Qiagen) with Ultra-turrax (IKA). A part of the 
homogenate was extracted using the RNeasy Fibrous Tissue Mini-Kit (Qiagen). 
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4.16 Microarray analysis  
4.16.1 Microarray chip design 
The software OligoArray 2.1 was used to design oligonucleotide probes for 
microarray. Whole genome Rattus norvegicus mRNA database was obtained from the ftp 
server of The National Center for Biotechnology Information (NCBI) from the address 
ftp://ftp.ncbi.nih.gov/genomes/R_norvegicus/RNA/. Input parameters for probes selection 
were as described in Tab. 6. 
Probe length 48-52 bp 
GC content 30% - 70% 
Melting temperature of probe 86 – 90 °C 
Melting temperature of secondary structures of 
probes  - limits for probe rejection 
65 °C 
Max. distance of probe from  3’ end 4000 bp 
Minimal distance between probes 50 bp 
Forbidden sequences AAAAA, TTTTT, CCCCC, GGGGG 
Tab. 6: Parameters for OligoArray 2.1 for probe design. 
 
The list of genes is shown in Tab. 7. These genes were used in the first part of this study 
(effect of Hyiodine and hyaluronic acid in Wistar rats). Genes shown in Tab. 7 with changes 
shown in Tab. 8 were used in the second part of this study, in the studies of wound repair on 
ZDF rats.
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name gene symbol REFSEQ ID name gene symbol REFSEQ ID
hyaluronan synthase1 (LOC282821) HAS1 NM_172323 matrix metalloproteinase 2 (72 KDa type IV collagenase) (Mmp2) mmp-2 NM_031054
hyaluronan synthase 2 (Has2) HAS2 NM_013153 matrix metalloproteinase 3 (Mmp3) mmp-3 NM_133523
hyaluronan synthase 3 (Has3) HAS3 NM_172319 matrix metalloproteinase 7 (Mmp7) mmp-7 NM_012864
hyaluronidase 1 (Hyal1) hyal1 NM_207616 matrix metalloproteinase 9 (gelatinase B, 92-kDa type IV collagenase) mmp-9 NM_031055
hyaluronidase 2 (Hyal2) hyal2 NM_172040 matrix metalloproteinase 13 (Mmp13) mmp-13 XM_343345
hyaluronidase 3 (Hyal3) hyal3 NM_207599 matrix metalloproteinase 12 (Mmp12) mmp-12 NM_053963
CD44 antigen (Cd44) cd44 NM_012924 matrix metalloproteinase 14 (membrane-inserted) (Mmp14) mmp-14 NM_031056
hyaluronan mediated motility receptor (Hmmr) RHAMM NM_012964 mannose-binding protein associated serine protease-1 (Masp1) P100=masp1 NM_022257
toll-like receptor 4 (Tlr4) TLR4 NM_019178 tissue inhibitor of metalloproteinase 1 (Timp1) TIMP1 NM_053819
tissue inhibitor of metalloproteinase 2 (Timp2) TIMP2 NM_021989
CD47 antigen (Rh-related antigen, integrin-associated signal transducer) IAP4 = CD 47 NM_019195 tissue inhibitor of metalloproteinase 3 (Timp3) TIMP3 NM_012886
inhibitor of apoptosis protein 1 (Birc3) BIRC3 NM_023987
apoptosis inhibitor 2 (Api2) API2 NM_021752 aggrecan 1 (Agc1) Agc1 NM_022190
Bcl2-associated X protein (Bax) bax NM_017059 biglycan (Bgn) bgn NM_017087
v-myc avian myelocytomatosis viral oncogene homolog (Myc) c-myc NM_012603 decorin (Dcn) Dcn NM_024129
Bcl-x alpha bcl-x alpha U72350 lumican (Lum) lum NM_031050
B-cell leukemia/lymphoma 2 (Bcl2) bcl-2 NM_016993 syndecan 1 (Sdc1) sdc1 NM_013026
caspase 3 (Casp3) caspase-3 NM_012922 syndecan 3 (Sdc3) sdc3 NM_053893
caspase-8 (Casp8) caspase-8 NM_022277 syndecan 4 (Sdc4) sdc4 NM_012649
tumor protein p53 (Tp53) p53 NM_030989 heparan sulfate core protein precursor (HSPG) (Perlecan) plc XM_233606
proliferating cell nuclear antigen (Pcna) PCNA NM_022381
p21 (CDKN1A)-activated kinase 2 (Pak2) p21 NM_053306 connective tissue growth factor (Ctgf) CTGF NM_022266
endothelin 1 (Edn1) Edn1 NM_012548
desmin (Des) desmin NM_022531 fibroblast growth factor 2 (Fgf2) FGF2 NM_019305
glial fibrillary acidic protein (Gfap) GFAP NM_017009 interleukin 1 beta (Il1b) IL1b NM_031512
mitogen activated protein kinase 1 (Mapk1) MAPK1 NM_053842 interleukin 4 (Il4) IL-4 NM_201270
interleukin 6 (Il6) IL-6 NM_012589
Rattus norvegicus nitric oxide synthase 2, inducible (Nos2) iNOS, NOS2 NM_012611 interleukin 10 (Il10) IL-10 NM_012854
nitric oxide synthase 3, endothelial cell (Nos3) NOS3 NM_021838 interleukin 12b (Il12b) IL-12b NM_022611 
ECM / ligamentous proteins neurotrophin 3 (Ntf3) NT-3 NM_031073
neural cell adhesion molecule 1 (Ncam1) N-CAM NM_031521 platelet derived growth factor, alpha (Pdgfa) PDGFa NM_012801
vitronectin (Vtn) Vtn NM_019156 Platelet-derived growth factor (Pdgfb) PDGFb XM_343293
thrombospondin 2 (TSP-2) Tsp-2 XM_214778 transforming growth factor, beta 1 (Tgfb1) TGFb1 NM_021578
thrombospondin 1 (Tsp1) Tsp-1 AF309630 transforming growth factor, beta 3 (Tgfb3) TGFb3 NM_013174
secreted acidic cysteine rich glycoprotein (Sparc) SPARC NM_012656 tumor necrosis factor  superfamily, member 2 (Tnf) TNFa NM_012675
reelin (Reln) Reln NM_080394 vascular endothelial growth factor (Vegf) VEGF NM_031836
secreted phosphoprotein 1 (Spp1) spp1 Opn NM_012881 insulin-like growth factor 1 (Igf1) Igf1 NM_178866
alpha-2-macroglobulin (A2m) a2m NM_012488 relaxin 1 (Rln1) Rln1 NM_013413
fibulin 5 (Fbln5) Fbln-5 NM_019153
fibulin 2 (Fbln2) Fbln-2 XM_232197 actin, beta (Actb) Actb NM_031144
laminin, beta 2 (Lamb2) lamb2 NM_012974 Rat 18S rRNA sequence 18S RNA X01117
fibronectin 1 (Fn1) Fn1 NM_019143 glyceraldehyde-3-phosphate dehydrogenase (Gapd) GAPD NM_017008.2
fibrillin-1 (Fbn1) Fbn1 NM_031825
fibrillin-2 (Fbn2) Fbn2 NM_031826 transforming growth factor, beta receptor 3 (Tgfbr3) Beg= TGFBR3 NM_017256
elastin (Eln) Eln XM_341061 intercellular adhesion molecule 1 (Icam1) ICAM-1 NM_012967
procollagen, type I, alpha 2 (Col1a2) Col1a2 NM_053356 laminin receptor 1 (67kD, ribosomal protein SA) Lamr1 NM_017138
collagen, type III, alpha 1 (Col3a1) Col3a1 XM_343563 Integrin, alpha 5 (fibronectin receptor, alpha) Itga5 XM_235707
collagen, type V, alpha 1 (Col5a1) Col5 NM_134452 integrin, alpha 6 (Itga6) Itga6 XM_215984
similar to alpha-3 type IV collagen (LOC363265) col4 XM_343607 integrin beta 1 (Itgb1) Itgb1 NM_017022





Apoptosis / Cell cycle
Proteases and inhibitors
House keeping
Cytokines a growth factors
Proteoglycans




name gene symbol REFSEQ ID group
galectin-1                   Lgals1 NM_019904 Receptors
galectin-3 Lgals3 NM_031832 Receptors
hsp-47 gp46 NM_017173.1 ECM / ligamentous proteins
laminin M (α2) Lama2 XM_219866 ECM / ligamentous proteins
plasminogen plg NM_053491.1 ECM / ligamentous proteins
plasminogen activator Plat NM_013151 ECM / ligamentous proteins
plasminogen activator inhibitor (Rattus norvegicus serine (or cysteine) peptidase inhibitor, clade E, member 1 (Serpine1)) PAI-1 NM_012620.1 ECM / ligamentous proteins
tissue transglutaminase, 2 (C polypeptide) Tgm2 NM_019386 ECM / ligamentous proteins
transforming growth factor, beta 2 Tgfb2 NM_031131 Cytokines a growth factors
Rattus norvegicus nitric oxide synthase 1, neuronal (Nos1) Nos1 NM_052799 NOS
PREDICTED: Rattus norvegicus matrix metalloproteinase 1b (interstitial collagenase) (predicted) mmp1 XM_235849  Proteases and inhibitors
Rattus norvegicus matrix metallopeptidase 10 (Mmp10) mmp10 NM_133514 Proteases and inhibitors
Rattus norvegicus bone morphogenetic protein 6 (Bmp6) bmp6 nm_013107 Cytokines a growth factors
PREDICTED: Rattus norvegicus chondroitin sulfate proteoglycan 2 (Cspg2) versican XM_215451.4 Proteoglycans
Rattus norvegicus macrophage expressed gene 1 (Mpeg1) mpeg1 NM_022617 Inflammation 
Rattus norvegicus S100 calcium binding protein A9 (calgranulin B)  (S100a9). mrp14 NM_053587 Inflammation 
Rattus norvegicus syndecan 2 (Sdc2). sdc2  NM_013082 Proteoglycans
Rattus norvegicus plasminogen activator, urokinase (Plau) plau NM_013085 Proteases and inhibitors
Rattus norvegicus matrix metallopeptidase 8 (Mmp8) mmp8 NM_022221 Proteases and inhibitors
Rattus norvegicus secretory leukocyte peptidase inhibitor (Slpi) slpi NM_053372.1 Proteases and inhibitors
Rattus norvegicus gremlin 1 homolog, cysteine knot superfamily (Xenopus laevis) (Grem1) grem1 NM_019282.1 Cytokines a growth factors
Rattus norvegicus angiopoietin 1 (Angpt1). angpt1 NM_053546.1 Cytokines a growth factors
PREDICTED: Rattus norvegicus angiopoietin 2 (Angpt2). angpt2 XM_344544.3 Cytokines a growth factors
PREDICTED: Rattus norvegicus tumor necrosis factor alpha induced protein 6 (Tnfaip6). Tnfaip6 XM_001065494 Cytokines a growth factors
Rattus norvegicus laminin, alpha 3 (Lama3) lama3 NM_173306.1 ECM / ligamentous proteins
PREDICTED: Rattus norvegicus laminin, beta 3 (Lamb3) lamb3 XM_223087.4 ECM / ligamentous proteins
PREDICTED: Rattus norvegicus lamimin, gamma 2 (Lamc2) lamc2 XM_213902.4 ECM / ligamentous proteins
PREDICTED: Rattus norvegicus laminin, beta 1 (predicted) (Lamb1_predicted) lamb1 XM_216679.4 ECM / ligamentous proteins
PREDICTED: Rattus norvegicus laminin, gamma 1 (Lamc1) lamc1 XM_341133.3 ECM / ligamentous proteins
inhibitor of apoptosis protein 1 (Birc3) BIRC3 NM_023987 Apoptosis / Cell cycle
apoptosis inhibitor 2 (Api2) API2 NM_021752 Apoptosis / Cell cycle
caspase-8 (Casp8) caspase-8 NM_022277 Apoptosis / Cell cycle
tumor protein p53 (Tp53) p53 NM_030989 Apoptosis / Cell cycle
desmin (Des) desmin NM_022531 Cytoskelet
glial fibrillary acidic protein (Gfap) GFAP NM_017009 Cytoskelet
ADDED
REMOVED 
Tab. 8: List of assayed transcripts, their abbreviations and reference numbers according to NCBI. Changes in microarray design for the study of 





4.16.2 cDNA synthesis, biotin-dUTP labeling, hybridization  
The procedure was based on the recommendation of the manufacturer (Bioscience, 
Jena – previously Clondiag). After the binding of random primers, RNA was transcribed 
to the cDNA using reverse transcriptase MuMLV (Fermentas) and 4 deoxyribonucleotides 
(Abgene) plus biotin labeled deoxyuridintriphosfate (Fermentas). cDNA was then hybridized 
with the probes on the array tube (AT) chip surface, which contained immobilized 50 bp 
DNA oligonucleotides probes specific for selected genes. Detailed procedure is described 
below. 
4.16.2.1 Materials 
 20x SSPE, 20x SSC (Invitrogen) 
 3DNA buffer : 250 mM Na2HPO4(Penta, p.a),  4,5% SDS (Amresco), 1 mM EDTA 
(Sigma), 1xSSC, pH = 7.2 
 HRP-streptavidine conjugate (Pierce, 1 mg/ml, 21130) 
 Blocker Casein in PBS (1% casein, Pierce, 37528) 
 deoxy nucleotides (100 mM, AB gene) 
 YM-30 columns (Millipore) 
 True Blue peroxidase substrate (KPL, 71-00-67, 10ml) 
4.16.2.2 cDNA synthesis and purification procedure 
The mixture of 26 µl of RNA with 3 µl of random hexamer primers (Invitrogen, 
3 µg/µl) was prepared. RNA was denaturated by incubation at 65 °C for 10 minutes, and then 
was put on ice. During the denaturation RT-mix was prepared for all the samples according to 










Reagent Volume [µl] 
5x RT buffer (Fermentas) 10 
Nucleotide mix(5 mM dATP, 5 mM dGTP, 5 mM dCTP, 3 mM dTTP) 1.5 
Biotin-dUTP 1 mM (Fermentas) 3 
MuMLV- RT – 200U/µl (Fermentas) 2 
RNAse free H2O (Qiagen) 4.5 
Total 1x RT-mix volume 21 µl 21 
Total volume (RTmix + RNA sol. + hexamers)  50 
Tab. 9: cDNA master mix for microarray for one reaction 
 
The reaction was done in a thermocycler at 25 °C for 10 minutes, then at 42 °C for 120 
minutes. 10 µl of NaOH (1M) was added and incubated at 65 °C in thermocycler for 10 
minutes to denaturate RNA. Meanwhile 430 µl of ddH20 was added to YM-30 columns. 10 µl 
of 1M HCl was added to tubes with cDNA to neutralize the solution. Neutralized cDNA 
solution was applied on the columns prefilled with H20. Columns were centrifuged at 13000 g 
at 20 °C for 8 minutes, the permeate was removed and 450 µl of ddH20 was added to columns 
to wash cDNA. Last centrifugation/washing step was repeated once more. The eluate of 
cDNA was transferred to clean tubes. If necessary the eluate was concentrated in a freeze 
dryer connected to a vacuum pump. The volume was adjusted with H20 to 12 µl. cDNA 
concentration and purity was measured at UV/VIS spectrophotometer at 260 and 280 nm 
using 2 µl cDNA. 
4.16.2.3 Hybridization procedure 
Array tubes were prewashed twice with 500 µl of 3DNA buffer (30 °C / 5min and  
50 °C / 5min) in thermomixer at 550 rpm. 10 µl of labeled cDNA was mixed with 90 µl, 
denaturated at 95 °C and cooled on ice of one minute. Then the solution was added to array 
tube (AT) and hybridized overnight at 50 °C in thermomixer at 550 rpm. After the 
hybridization ATs were washed with  500 µl of 2xSSC + 0.2% SDS at 30 °C for 5 min then 
with 2xSSC at the room temperature for 5 min and finally with 0.2xSSC at room temperature 
for 5 min. The unspecific background was blocked with 500 µl of 0.1% casein in 6xSSPE + 
0.1% SDS at 30 °C for 30 min. 2 µl the HRP-streptavidin conjugate (1:100 in PBS) with 98 µl  
3DNA buffer at 30 °C was added for 30 min. In all incubation steps ATs were incubated at 





4.16.2.4 Washing and signal capturing procedure 
The washing procedure was done according to Tab. 10. Cleansing of the bottom of AT 
with a micro-fiber cloth and checking in AT reader. The enzyme reaction was started by 
adding 100 µl of True Blue peroxidase substrate.  The signal of the array is captured in AT 
reader (ATR 01, CloneDiag) with open tubes. The AT reader was controlled using IconoClust 
array imaging software. The signal was captured at 25 °C for 15 minutes in 1 minute 
intervals.  The images were analyzed using IconoClust software and bad spots were manually 
removed. The data were exported to MS Excel.  
2xSSC+0.01% Triton 500 µl RT (room temp.)/5 min 550 rpm on vortex 
2. 2xSSC 500 µl RT/5 min 550 rpm on vortex 
3. 0.2xSSC 500 µl RT/5 min 550 rpm on vortex 
Tab. 10: Washing steps of AT procedure 
 
4.17 Analysis of mRNA gene expression using quantitative RT-PCR 
4.17.1 Materials 
 High-Capacity cDNA Archive kit (Applied Biosystems, PN 4322171) 
 total RNA (1 µg) 
 Universal TaqMan Master mix, No Amperase UNG (Applied Biosystems, PN 
4324018) 
 Fluorescent TaqMan probes with primers - Gene Expression Assay (Applied 
Biosystems, PN 4331182) 
 Real-time PCR instrument able to detect fluorescent probes labeled with VIC 
a FAM (Applied Biosystems ABI 7500 FAST, ABI 7900) 
 SDS software 1.3.1 (Applied Biosystems) 
 MicroAmp Fast 96-Well Reaction Plate (0.1 mL, Applied Biosystems, PN 
4346907) 





Applied Biosystems Gene Expression assays probes/primers sets were used in this study  
(Tab. 11). 
Gene (rat) Assay ID RefSeq accession number 
rac1 subunit of NADPH oxidase Rn01412765_m1 NM_134366 
rac2 subunit of NADPH oxidase Rn01504461_g1 NM_001008384 
catalase Rn00560930_m1 NM_012520 
glutathion reductase 1 Rn00588153_m1 NM_053906 
glutathion peroxidase 1/7 Rn00577994_g1 NM_030826 
superoxide dismutase 1, cytoplasm Rn00566938_m1 NM_017050 
superoxide dismutase 2, mitochondrial Rn00566942_g1 NM_017051.2 
superoxide dismutase 3, extracellular Rn00563570_m1 NM_012880.1 
thioredoxin1 Rn00587437_m1 NM_053800 
heme oxygenase 1 Rn00561387_m1 NM_012580.2 
p22-phox subunit of NADPH oxidase Rn00577357_m1 NM_024160 
myeloperoxidase Rn01460205_m1 XM_220830 
Tab. 11: List of analyzed genes using TaqMan® Gene Expression assays. 
 
4.17.2 Procedure 
4.17.2.1 Synthesis of cDNA (reverse transcription of RNA) 
The RT premix was prepared according to the Tab. 12 and 50 µl of the RT premix was 
pipetted to each tube. 1 µg of RNA in total volume of 50 µl was added to each reaction and 
incubated in a thermocycler at 25 °C for 10 min, then at 37 °C for 120 min. 
Reagent 1 reaction [µl] 
10x RT buffer 10 
25x dNTP mixture 4 
10x Random primers 10 
Multiscribe RT (50 U/µl) 5 
RNase free H20 21 
total PREMIX 50 
RNA 1 µg 50 
total reaction volume 100 






4.17.3 Realtime-PCR amplification 
Every cDNA sample was diluted with water in ratio 1:10 and calibration samples also 
in ratios 1:100 and 1:1000. The master mix was prepared with probe according to Tab.  13. 
Reagent 1 reaction [µl] 
2 X TaqMan master mix 10 
probe + primers 1 
Total master mix volume 11 
Tab.  13 : Preparation of TaqMan probe PCR reaction. 
 
11 µl of the master mix was added to each well of the plate. 9 µl of diluted cDNA was added 
to wells. The plate was sealed and put into the qPCR instrument. The program ABI SDS using 
absolute quantification module was used. Standard thermal program was used as follows :  
50 °C - 2 min, 95 °C - 10 min and 40 cycles (95 °C - 15 s, 60 °C - 1 min). Data were analyzed 
using SDS software with absolute quantification module. Calibration curve was calculated 
from the signal of three dilutions of the calibration sample (quantity was made equal to 1 for 
1:10 dilution, 0.1 for 1:100 dilution and 0.01 for 1:1000 dilution).  
4.18 Immunohistochemistry 
The immunohistochemistry procedures were done in part by Vlasta Tkáčová (as a part 
of her diploma thesis and her summer job at the Faculty of Medicine in Hradec Králové) 
and Burak Tahmazoglu (as a part of his summer fellowship at the Faculty of Medicine 
in Hradec Králové) under the tuition and supervision of the author of this thesis.  
4.18.1 Chemicals and materials 
 Xylene (P-Lab), ethanol p.a. (Lach-Ner), hydrogen peroxide p.a. (Riedel-de Haën), 
bovine fetal serum (Gibco), citric acid p.a. (Lach-Ner), sodium citrate p.a. (Lach-Ner), 
hydrochloric acid (Penta), sodium chloride (Lach-Ner), sodium hydrogen phosphate 
dihydrate p.a. (Fluka), potassium dihydrogen phosphate (Lachema), formaldehyde 
(Sigma) 
 Polyclonal rabbit antibody IgG against IL-6 (Abcam, ab6672) 
 Polyclonal rabbit antibody IgG against MPO (Abcam, ab9535) 






 Rabbit polyclonal antibody against MMP-13 (Santa Cruz, sc-30073) 
 DakoCytomation LSAB+ System – HRP; Biotinylated link universal, Streptavidin-HRP 
(DakoCytomation, K0690) 
 DAB Substrate – Chromogen system; DAB chromogen, DAB substrate buffer 
(DakoCytomation – K3466) 
 DPX mountant for histology (Fluka) 
 Hematoxylin solution according to Mayer (Sigma, 51275) 
 PBS buffer (NaCl 9.0 g ;KH2PO4 0.144 g; Na2HPO4.2H2O 0.528 g per liter , pH 7.4) 
 Citrate buffer  
o Solution A: 0.63 g of citric acid in 30 ml of distilled water  
o Solution B: 1.32 of sodium citrate in 45 ml of distilled water 
o Fresh solution of citrate buffer was prepared by adding 9 ml of solution A to 41 ml of 
solution B, adding 450 ml of distilled water. pH was adjusted to 6.0. 
 Casein blocking solution 1% (Pierce #37528) 
 Microscope Nikon Eclipse 80i with objectives (4x, 20x, 60x), camera Nikon DS-Fi1 
 Nis – Elements AR 3.0 software and camera drivers: Nikon DS-U2/L2 USB, 5.03 
4.18.2 Procedure 
Hydration and paraffin removal was done by incubating samples in xylene for 3 x 5 
min, 100% ethanol for 5 min, 96% ethanol for 5 min, 80% ethanol for 5 min, 75% ethanol for 
5 min and finally in distilled water for 5 min. Antigen demasking was done by boiling in 
microwave oven in citrate buffer at 800 W / 2.5 min and then at 200 W / 12.5 min. The 
unspecific peroxidase reaction in samples was blocked by 3% H2O2 for 15 min. Then samples 
were washed three times in PBS for 5 min and in 5% serum or 0.25% casein blocking solution 
for 30 min. Samples were incubated with PBS solution of antibody for 1 h at 1:50 dilution for 
MPO, at 1:400 for IL-6, at 1:200 for MMP-3 and 1:100 for MMP-13. Slides were washed in 
PBS three times for 5 min. For the attachment of secondary antibody, the samples were 
incubated in biotinylated link universal solution for 15 min and then washed in PBS buffer 3 
times for 5 min. Samples were then incubated with enzyme conjugate streptavidin HRP for 15 
min and washed in PBS buffer 3 times for 5 min. Stain development was performed with 
DAB chromogen during 10 min incubation for MPO and 4 min for others antigens. Samples 
were washed twice for 2 minutes with PBS. Nucleus was stained with hematoxylin for 5 min 





75% ethanol for 5 min, 80% ethanol for 5 min, 96% ethanol for 5 min, 100% ethanol for 5 
min and xylene 3 x 5 min. Then the slides were mounted and covered with cover slip. The 
samples were observed and images were captured using Microscope Nikon Eclipse 80i with 
camera settings as follows: contrast – high, white autobalance, autoexposition AE+1, high 






5.1 Part 1: Effects of hyaluronan and iodine on wound contraction and 
granulation tissue formation in rat skin wounds 
5.1.1 Determination of wound contraction 
Wound contraction in control rats was rapid in the first week of the experiment and 
it was almost complete by day 15 when less than 5% of the wound area was not covered with 
epithelium. The contraction was significantly accelerated in the first few days by the mixture 
of HA1200 and KI3 (Hyiodine) treatment. The wound area in control rats on day 5 was 60% 
of the original size. When the wounds were treated with Hyiodine, this percentage was 
reached almost 2 days earlier (Fig. 8).  
 
Fig. 8: Wound area as a percentage of the original area measured immediately after wounding. Data 





5.1.2 Appearance of the contractile wounds 
The appearance of wound on day 3 and day 5 is illustrated in Fig. 9. The wounds 
treated with Hyiodine did not adhere to the bandage and bleeding was little compared 
to control group (Fig. 9).  
 
Fig. 9: Photographs of wounds treated with Hyiodine (H) vs. control (C, saline). Note the increased 
bleeding after the removal of bandage in control group (arrow).  
5.1.3 Histological analysis of contractile wounds 
Fig. 10 shows the thickening of the epithelium in the wound on day 7 of Hyiodine 
treatment. The thickness of the epithelial layer measured immediately after wounding was 
30 μm. It increased to 102 μm in both saline and Hyiodine treated wounds on day 3. However, 
it was 109 μm and 146 μm, respectively, in saline and in Hyiodine treated wounds on day 7. 
The difference was statistically significant. 
 
 
Fig. 10: Histological sections of saline (a) and Hyiodine (b) treated wounds stained with blue 







5.1.4 Analysis of the granulation tissue from permanent wound 
Seven-day treatment of GT with the mixture of HA1200 and KI3 (Hyiodine) resulted 
in 18% increase in the wet weight of the GT compared to saline treatment. The changes 
caused by HA1200 and by KI3 alone were smaller and were not statistically significant. 
The concentration of hydroxyproline, the index of collagen, was decreased by Hyiodine 
treatment when compared to saline or other solutions but little changes were found in total 
hydroxyproline content (Tab. 14). 




Weight (mg) 363 ± 18 410 ± 16 375 ± 14 428 ± 17 
a
 409 ± 27 
% dry weight 16.0 ± 0.9 16.1 ± 0.7 16.1 ± 0.6 15.9 ± 0.8 18.3 ± 1.2 
Hyp concentration 
(mg/g) 
4.03 ± 0.22 3.99 ± 0.19 4.25 ± 0.24 3.66 ± 0.14 
b
 3.88 ± 0.22 
Hyp content (mg) 1.45 ± 0.09 1.63 ± 0.09 1.58  ± 0.09 1.56 ± 0.08 1.56 ± 0.11 
Tab. 14: Changes in granulation tissue weight, dry weight and hydroxyproline (hyp) content after 
treatment of the wounds with saline, hyaluronan, iodine or Hyiodine. Means ± SEM. Statistical 
significance (p < 0.05). a) Hyiodine vs. saline, b) Hyiodine vs. HA1200. 
5.1.5 Analysis of the crust and exudate of permanent wound 
The crust was formed on the top of the granulation tissue. It could not be separated 
from the exudate gel that was abundant especially after Hyiodine treatment (Fig. 11). 
 
Fig. 11: Photograph of permanent wound on day 7, after the removal of plastic ring, C – control 
wound, H – wound treated with Hyiodine. Note the presence of moist gel on the top of Hyiodine 
treated wound. 
 
HA1200 caused a 37% increase in the crust/exudate weight and KI3 alone did not have any 
effect. When applied together, these substances increased the weight of the layer by 351% 





Protein concentration was similar in all groups but the total amount of protein was by far the 
highest in the Hyiodine group, 349% when compared with saline. The source of the protein 
might be blood plasma. We therefore studied the composition of the protein mixture by SDS-
PAGE. Fig. 12 shows that the protein pattern of 4 different exudate samples resembled that of 
plasma and serum. The band at 66 kDa corresponding to albumin was prominent.  
 
Fig. 12: SDS-PAGE of proteins contained in the crust/exudate. alb – bovine serum albumin, ser – rat 
blood serum, pl – rat blood plasma, 1,2,3,4 – different samples of crust/exudate after treatment with 
Hyiodine, GT – granulation tissue. 
 
Total uronic acid content in dried crust/exudate was increased about 3fold by HA1200 and 
14fold by Hyiodine when compared to saline (Tab. 15).  
Crust/exudate Saline HA11 HA1200 





95.0± 19.9 153.3 ± 22.3 130.0 ± 31.0 428.0 ± 81.2 
a,c,d
 96.1 ± 25.1 
Protein concentration 
(% dry weight) 
90.6 ± 9.2 91.4 ± 5.9 93.8 ± 6.8 92.5 ± 9.5 85.3 ± 8.9 
Protein content  
(mg) 
36.8 ± 7.1 38.7 ± 5.6 36.6 ± 9.0 128.3 ± 27.0 
a,b,c
 48.2 ± 11.3 
Uronic acid concentr. 
(% dry weight) 
1.38 ± 0.22 1.25 ± 0.14 2.83 ± 0.52 4.07 ± 0.64
 a,b,d
 1.42 ± 0.20 
Uronic acid content 
(mg) 
0.37 ± 0.06 0.49 ± 0.05 1.08 ± 0.34 5.10 ± 0.94
 a,b,c,d
 0.53 ± 0.10 
Tab. 15: Changes in the weight, protein and uronic acids content in the crust and exudate after 
treatment with saline, hyaluronan, iodine or Hyiodine. Means ± SEM. Statistical significance 






5.1.6 Gene expression analysis in granulation tissue by DNA arrays 
The mean expression of 92 genes studied was made equal to 1. Studied genes were 
cell cycle regulators, cytokines and growth factors, part of ECM, proteinases and their 
inhibitors and receptors. The results of their expression are shown in Tab. 16. No statistically 
significant differences were found by DNA arrays when Hyiodine- and saline-treated tissues 
were compared. Nonetheless, it was observed that many ECM proteins and proteoglycans 
mRNAs were highly expressed in the granulation tissue (collagens 1, 3 and 5, fibrilin-1, 
fibronectin, osteonectin, osteopontin, thrombospondin-1, vitronectin, biglycan, decorin, 
lumican, perlecan). 
Substance Group saline HA11 HA1200 KI3 HYIO 
API2 Apoptosis / Cell cycle 0.09 0.12 0.17 0.07 0.11 
bax Apoptosis / Cell cycle 0.83 0.92 0.97 0.72 0.74 
bcl-2 Apoptosis / Cell cycle 2.58 2.36 2.24 2.57 2.52 
bcl-x alpha Apoptosis / Cell cycle 1.93 1.81 1.72 1.90 1.99 
BIRC3 Apoptosis / Cell cycle 0.07 0.08 0.12 0.04 0.08 
caspase-3 Apoptosis / Cell cycle 0.51 0.57 0.60 0.39 0.47 
caspase-8 Apoptosis / Cell cycle 0.10 0.10 0.14 0.07 0.15 
c-myc Apoptosis / Cell cycle 1.05 1.14 1.08 0.98 1.08 
IAP4 Apoptosis / Cell cycle 1.06 0.98 0.91 0.87 0.94 
p21 Apoptosis / Cell cycle 0.57 0.55 0.55 0.48 0.53 
p53 Apoptosis / Cell cycle 0.20 0.22 0.27 0.20 0.22 
PCNA Apoptosis / Cell cycle 0.38 0.39 0.40 0.34 0.36 
CTGF Cytokines a growth factors 0.15 0.13 0.16 0.11 0.14 
Edn1 Cytokines a growth factors 0.17 0.15 0.20 0.15 0.18 
FGF2 Cytokines a growth factors 0.67 0.47 0.56 0.54 0.62 
Igf1 Cytokines a growth factors 0.69 0.65 0.62 0.64 0.56 
IL-10 Cytokines a growth factors 0.26 0.21 0.27 0.20 0.22 
IL-12b Cytokines a growth factors 0.08 0.06 0.10 0.07 0.08 
IL1b Cytokines a growth factors 0.10 0.13 0.16 0.09 0.13 
IL-4 Cytokines a growth factors 0.08 0.09 0.09 0.10 0.10 
IL-6 Cytokines a growth factors 0.19 0.20 0.21 0.14 0.20 
NT-3 Cytokines a growth factors 0.10 0.07 0.06 0.04 0.12 
PDGFa Cytokines a growth factors 0.24 0.25 0.25 0.18 0.23 
PDGFb Cytokines a growth factors 2.34 2.17 2.20 2.46 2.36 
Rln1 Cytokines a growth factors 0.23 0.16 0.19 0.14 0.19 
TGFb1 Cytokines a growth factors 0.66 0.73 0.75 0.58 0.62 
TGFb3 Cytokines a growth factors 0.26 0.20 0.26 0.19 0.22 
TNFa Cytokines a growth factors 0.24 0.22 0.32 0.22 0.27 
VEGF Cytokines a growth factors 1.56 1.89 1.79 2.06 2.13 
desmin Cytoskelet 3.20 3.23 3.16 3.55 3.35 





a2m ECM proteins 0.67 0.61 0.70 0.47 0.55 
col18a1 ECM proteins 0.61 0.60 0.58 0.61 0.59 
Col1a2 ECM proteins 3.15 3.35 3.23 3.52 3.09 
Col3a1 ECM proteins 2.97 3.19 3.13 3.47 2.99 
col4 ECM proteins 0.31 0.31 0.30 0.25 0.31 
Col5 ECM proteins 1.87 1.97 1.86 1.88 1.85 
Eln ECM proteins 1.34 1.33 1.32 1.27 1.40 
Fbln-2 ECM proteins 0.67 0.56 0.62 0.57 0.59 
Fbln-5 ECM proteins 0.23 0.21 0.27 0.17 0.20 
Fbn1 ECM proteins 2.46 2.60 2.43 2.80 2.70 
Fbn2 ECM proteins 0.26 0.25 0.24 0.18 0.24 
Fn1 ECM proteins 1.06 1.04 1.12 1.10 1.19 
lamb2 ECM proteins 0.15 0.09 0.13 0.11 0.13 
Reln ECM proteins 1.07 0.87 0.92 0.98 0.90 
SPARC – ON ECM proteins 3.12 3.38 3.21 3.63 3.28 
spp1 - OPN ECM proteins 2.69 3.00 2.90 2.66 2.82 
Tsp-1 ECM proteins 1.20 1.03 1.05 1.14 1.14 
Tsp-2 ECM proteins 0.80 0.76 0.71 0.70 0.73 
Vtn ECM proteins 1.15 1.08 1.03 1.02 0.98 
18S RNA House keeping 2.74 2.78 2.84 2.92 2.58 
Actb House keeping 2.97 3.13 3.15 3.29 2.79 
GAPD House keeping 0.43 0.35 0.46 0.40 0.34 
cd44 Hyaluronan metabolism 0.43 0.48 0.46 0.34 0.47 
HAS1 Hyaluronan metabolism 0.49 0.43 0.48 0.40 0.48 
HAS2 Hyaluronan metabolism 0.32 0.36 0.38 0.27 0.32 
HAS3 Hyaluronan metabolism 0.00 0.02 0.02 0.01 0.02 
hyal1 Hyaluronan metabolism 0.54 0.50 0.57 0.45 0.53 
hyal2 Hyaluronan metabolism 1.68 1.75 1.65 1.98 2.09 
hyal3 Hyaluronan metabolism 1.28 1.02 1.13 1.00 1.01 
RHAMM Hyaluronan metabolism 1.20 1.10 1.00 0.93 1.09 
TLR4 Hyaluronan metabolism 0.12 0.12 0.17 0.09 0.13 
iNOS NOS 0.35 0.33 0.37 0.21 0.33 
NOS3 NOS 0.07 0.07 0.12 0.08 0.10 
mmp-12 Proteinases and inhibitors 0.32 0.33 0.48 0.26 0.34 
mmp-13 Proteinases and inhibitors 0.65 0.52 0.59 0.50 0.63 
mmp-14 Proteinases and inhibitors 1.74 1.81 1.77 1.63 1.70 
mmp-2 Proteinases and inhibitors 1.38 1.48 1.42 1.58 1.64 
mmp-3 Proteinases and inhibitors 0.19 0.16 0.18 0.14 0.22 
mmp-7 Proteinases and inhibitors 0.75 0.65 0.69 0.65 0.66 
mmp-9 Proteinases and inhibitors 0.07 0.07 0.10 0.08 0.12 
P100 Proteinases and inhibitors 0.54 0.51 0.48 0.45 0.48 
TIMP1 Proteinases and inhibitors 2.04 1.94 1.90 2.06 1.98 
TIMP2 Proteinases and inhibitors 2.89 2.86 2.83 3.19 3.02 
TIMP3 Proteinases and inhibitors 0.49 0.45 0.49 0.41 0.43 
Agc1 Proteoglycans – ECM  0.00 0.02 0.01 0.00 0.02 
bgn Proteoglycans – ECM 1.20 1.08 1.18 1.05 1.12 





lum Proteoglycans – ECM 2.75 2.93 2.84 2.94 2.86 
plc Proteoglycans – ECM  3.34 3.42 3.39 3.77 3.35 
sdc1 Proteoglycans – transmemb. 0.45 0.37 0.44 0.42 0.42 
sdc3 Proteoglycans – transmemb. 0.08 0.06 0.10 0.07 0.09 
sdc4 Proteoglycans – transmemb. 0.38 0.42 0.45 0.30 0.42 
Beg Receptors 1.27 1.14 1.17 1.16 1.16 
ICAM-1 Receptors 0.59 0.61 0.59 0.47 0.58 
Itga5 Receptors 2.36 2.51 2.41 2.55 2.52 
Itga6 Receptors 0.61 0.62 0.60 0.52 0.56 
Itgb1 Receptors 1.19 1.13 1.11 1.09 1.09 
Itgb3 Receptors 0.32 0.34 0.37 0.27 0.35 
Lamr1 Receptors 1.81 1.86 1.73 1.88 1.87 
N-CAM Receptors 1.60 1.61 1.46 1.40 1.50 
MAPK1 Signal transduction  0.23 0.21 0.26 0.17 0.21 
average   1.00 1.00 1.00 1.00 1.00 
Tab. 16: Gene expression of selected genes in granulation tissue on day 7. For full gene names please 
refer to the methods. Values of highly expressed genes are bold (expression value > 1 in saline group). 
n = 14 - 15. 
5.1.7 Gene expression analysis in granulation tissue by quantitative RT-PCR  
Selected genes expression was also analyzed by qPCR. The results are shown in Tab. 
17. None of the studied genes were significantly differentially expressed in none 
of the studied groups. MMP-7 and osteopontin were non-significantly elevated in HA1200 
group and MMP-13 was slightly elevated in Hyiodine group. 
 
GENE Saline HA11 HA1200 HYIO KI3 
MMP-2 0.89±0.06 0.99±0.09 0.837±0.07 0.83±0.07 0.969±0.09 
MMP-7 4.32±1.22 4.9±1.53 7.27±1.83 2.65±0.54 2.14±0.53 
MMP-13 0.37±0.08 0.24±0.06 0.37±0.10 0.58±0.20 0.41±0.14 
Osteopontin 0.58±0.08 0.56±0.15 0.84±0.18 0.50±0.09 0.42±0.07 
COL1A2 0.39±0.06 0.42±0.08 0.34±0.13 0.33±0.10 0.34±0.11 
VEGF 1.27±0.18 1.39±0.17 1.32±0.24 1.33±0.25 1.27±0.17 
HYAL-2 1.13±0.08 1.24±0.10 1.11±0.06 1.04±0.06 1.11±0.06 
Tab. 17: Relative gene expression of selected genes in granulation tissue on day 7 as assayed by 








5.2 Part 2: Zucker Diabetic Fatty rat – a new model of impaired 
cutaneous wound repair with type II diabetes mellitus and obesity 
5.2.1 Animal breeding  
During the study it was necessary to optimize the conditions of ZDF animal breeding. 
We had very good results in breeding non-diabetic carrier (fa/+) males with non-diabetic 
carrier females (fa/+). In this case, the progeny was expected as follows: 25% of the offspring 
diabetic, 50% non-diabetic carriers, 25% non-diabetic non-carriers. It was also possible 
to interbreed diabetic male with non-diabetic carrier females. In this case the offspring were 
expected to be 50% of diabetic animals and 50% of non-diabetic carriers. The breeding was 
possible if the diabetes-predisposed males were young enough (usually < 15 week). 
Alternatively, it was possible to apply the food restriction (ad libitum regime was replaced 
with the recommended standard dose regime). In this case, rats did not become significantly 
obese and phenotypically diabetic and hence their fertility was better. In this section the term 
diabetic signifies the genotype (diabetes in not necessarily manifested in young animals). 
5.2.2 Genotypization of ZDF animals 
Typical results of genotypization are shown in Fig. 13 and Fig. 14. DNA for leptin 
receptor gene was first amplified by PCR and then the amplified fragment was cleaved by 
a restriction enzyme at the site of the potential mutation. In case of lepr mutation, 
the amplified part of the gene was cleaved and new bands appeared on the electrophoretogram 
(Fig. 14).  
 









Fig. 14: Electrophoresis image after enzymatic cleavage of PCR fragment with MspII. Bands for +/+ 
genotype are in region of 118 bp, for +/fa genotype in region 118, 79 and 39bp and for fa/fa genotype 
in region 79 and 39bp. The ladder is located on the left with 200bp/100bp/50bp/20bp/10bp fragments. 
The expected rate of genotype of progeny from carriers breeding was confirmed by PCR-
RFLP genotypization (Tab. 18). 
 
genotype amount rate % 
+/+ 18 26.5% 
fa/+ 32 47.1% 
fa/fa 18 26.5% 
total 68 100% 













5.2.3 Development of diabetes in ZDF rats   
Non-fasting glycemia was increased in diabetic males and usually began to increase 
significantly at the age of 12-14 weeks. It was 3fold higher at the age of about 20 weeks (Fig. 
15). However, the increase in glycemia was individual; there were animals in whom 
we observed high glycemia as early as the age of 12 weeks. In some animals glycemia began 
to increase at later age. 
 
 
Fig. 15: Changes in blood glycemia in ZDF males fed by Purina 5008. Means of five animals 
are shown. 
 
Non-fasting glycemia was increased in diabetic females during the development of diabetes, 
however, it did not increase to such an extent as in males. It reached the level 
of approximately 50% higher compared to controls at the age of 20 weeks (Fig. 16).  
 






5.2.3.1 Modification of diet and the effect on glycemia  
The diet had a profound effect on the development of glycemia. The diets H1 and HZ2 
with high content of saturated fat were able to induce high glycemia in female ZDF animals 
(Fig. 17). Please refer to the Materials and methods for the composition of H1 and HZ2.  
As early as after 6 weeks of feeding the special diet the glycemia was more than double that 
of the controls in H1 and HZ2 groups. At the end of the treatment the glycemia reached the 
values > 20 mmol/l, which is comparable with the levels observed in obese diabetic males fed 
PURINA 5008 at the age of 20 weeks.   
 
 
Fig. 17: The development of glycemia in ZDF females and the effect of “home-made” high-fat diet. 
The graph shows changes in glycemia with time as influenced by different diets H1, H2 a C13004. 
Dashed lines indicate non-diabetic control animals. Animals were 6 - 8 weeks old at the start of the 






5.2.4 Physiology of ZDF rats  
5.2.4.1 Growth curve of animals 
As shown in Fig. 18 there was an expected difference in the growth curves of diabetic 
and non-diabetic animals. The animals had similar weights at the age of 5 weeks. 
The difference was significant (p < 0.05) at the age of 11 weeks and further on. 
The difference increased until the age of about 13 weeks. Then, the difference increased 
at a slower pace. At the age of about 20 weeks the difference tended to be constant. After the 
age of 22 weeks it was observed that diabetic animal weight stagnated or even decreased 
(not shown) and non-diabetic animals tended to grow slowly. This was probably the results of 
severe metabolic problems. Animals had already very high glycemia and could not utilize 
glucose and insulin properly.  
 
 






The weight of 5 weeks old females was similar in both groups. The difference was 
significant (p < 0.05) at the age of 7 weeks and further on. The difference in weight increased 
at a steady pace during whole period of observation. After 22 weeks of age the difference 
between control and obese animals continued to increase (not shown). Females did not show 
signs of metabolic deterioration at such an extent that was observed in males.  
 





5.2.4.2 Physiological and blood parameters of ZDF animals 
The body weight of diabetic animals was increased in both sexes and it was more 
pronounced in females, doubling that of control (Tab. 19). Elevated glucose levels, on the 
other hand, were more pronounced in diabetic males. Diabetes in the ZDF rats was associated 
with higher levels of plasma insulin, PAI-1, leptin and CRP (Tab. 19) compared to controls. 
Levels of MDA were elevated in males (Tab. 19) and correlated with glycemia (R = 0.82, not 












Weight (g) n = 13-18 363 ± 7 466 ± 13 ** 1.3 218 ± 4 436 ± 7 ** 2.0 
Glucose 
(mmol/l) n = 13-18 
6.7 ± 0.2 17.8 ± 0.7 ** 2.7 7.3 ± 0.3 




(ng/ml)  n = 11-14 
1.28 ± 0.08 
10.8 ± 1.48 
** 
8.4 1.63 ± 0.15 




(ng/ml) n = 9-11 
2.45 ± 0.17 
4.89 ± 0.75 
** 
2 2.62 ± 0.21 




(pg/ml) n = 10-12 
62.7 ± 3.0 64.0 ± 5.1 1.02 64.4 ± 6.3 62.5 ± 4.6 0.97 
C-reactive protein 
(g/ml ) n = 7-10 
45.5 ± 5 62.5 ± 10.2 1.37 30.4 ± 3.3 




(ng/ml) n = 12-16 
5.05 ± 0.44 
39.1 ± 3.29 
** 
7.7 2.85 ± 0.39 




(mol/l) n = 6 
3.95 ± 0.29 
7.44 ± 0.94 
** 
1.88 4.26 ± 0.3 4.52 ± 0.34 1.06 
Tab. 19: Parameters of ZDF animals at the age of 18 - 20 weeks. Data are expressed as mean ± SEM, 






5.2.5 Wound closure of bandaged wounds in ZDF rats. 
The appearance of bandaged wounds is shown in Fig. 20. On day 0 there was visible 
underlying fat tissue in diabetic wounds. On day 5 and day 10 wounds were larger in diabetic 
animals than in the control ones. When the wounds were covered with gauze dressing, 
the crust formation was suppressed (Fig. 20) as the exudate was absorbed by the gauze. 
During the changes of gauze dressing the crust was usually removed with gauze and new crust 
formed afterwards.   
 
Fig. 20: Healing of excisional wounds in ZDF males and females. A: Photographs of bandaged 





Fig. 21 and Fig. 22 show that the healing progress of diabetic wounds was retarded in both 
sexes, resulting in healing times about 80% longer in males and 60% in females.  
 
 
Fig. 21: Wound healing of bandaged wounds - ZDF females. n = 5, mean ± SEM.  
**: p < 0.01, *: p < 0.05 (diabetic vs. non-diabetic) 
 
 
Fig. 22: Healing of bandaged wounds - ZDF males. n = 6 - 7, mean ± SEM. **: p < 0.01,  







5.2.6 Wound closure of non-bandaged wounds in ZDF rats. 
Fig. 23 illustrates the macroscopic appearance of non-bandaged wounds. Wound size 
diminution in diabetic males was significantly retarded during 10 days after wounding. 
The wounds were covered with a crust that was more pronounced in diabetic rats (Fig. 23). 
 
Fig. 23: Healing of excisional wounds. Photographs of wounds on day 0, day 5, day 10 and day 10 
without crust that was removed. Note large crusts over diabetic wounds on day 10. ND : non-diabetic, 
D : diabetic. 
 
In males, the wounds had a tendency to increase in size (peak on day 3, 106% of original size) 
and diminished to below their original size by day 6, whereas non-diabetic wounds were 
































Fig. 24: Wound size changes of excisional wounds – males. Data are shown as means ± SEM. 
 n = 9 - 12. **: p < 0.01 (diabetic animals compared to non-diabetic controls). 
 
In diabetic females, the wound size diminution was even more profoundly retarded. The 
wounds tended to increase in size (peak on day 5, 128% of original size) diminishing below to 
their original size by day 8, whereas non-diabetic wounds were already half of their original 
size at that time (Fig. 25).  
At the end of the experiment, on day 10, the male diabetic wounds were about 50% 






Fig. 25: Wound size changes of excisional wounds – females. Data are shown as means ± 
SEM. n = 8 - 10, **: p < 0.01 (diabetic animals compared to non-diabetic controls). 
 
In each group, the non-bandaged wound started to heal more slowly in comparison to the 
bandaged wound – the bandage helped initial contraction (please compare 
Fig. 25 Fig. 25  vs. Fig. 21, and Fig. 24 vs. Fig. 22). 
5.2.7 Histological analysis of adipose, epithelial, granulation and dermal tissue. 
The unwounded dermis on the back of animals was slightly thinner in diabetic 
animals, notably in males by 30% (Tab. 20). Diabetic skin contained a thick layer 
of underlying adipose tissue, most notably in females (Tab. 20, Fig. 26A). As a result 
the wounds in the diabetic females were deeper. The wound tissue retrieved on day 5 
contained a significant amount of adipose tissue in both non-diabetic ((37 ± 5)%) and diabetic 
animals ((70 ± 3)%) with significantly (p < 0.01) greater amount in diabetic animals (Fig. 
26B). Fibrous granulation tissue was thicker in non-diabetic animals and it covered the entire 
surface of the wound, whereas in diabetic animals the granulation tissue had been infiltrated 
by adipose tissue and covered the wound only partially, mainly at the periphery (Fig. 26B). 
On day 5, the thickening of new epithelium near the wound edge was clearly observed, 
however with little migration over the wound. The wound tissue retrieved on day 10 (Fig. 
26C) generally contained more granulation and fibrous tissue, and less adipose tissue 
compared to day 5. The granulation tissue in diabetic animals was poorly developed 





surface), and was infiltrated by adipose tissue (Fig. 26C). Diabetic wounds were characterized 
by an increased amount of crust (red in Fig. 26, Tab. 20). Large amount of poly-
morphonuclear infiltration was found under and inside the crust of diabetic animals. 
The proportion of adipose tissue in wound tissue was 4 to 5 times higher in diabetic than 
in non-diabetic animals (Tab. 20). The crust was 2 and 3 times thicker in diabetic animals 
in males and females, respectively (Tab. 20). Interestingly, the total length of the epithelial 










Dermis thickness in 
unwounded skin [m] 
1668 ± 52 1159 ± 44** 758 ± 23 683 ± 27 
Adipose tissue thickness in 
unwounded skin [m] 
58 ± 19 509 ± 104** 45 ± 6 1204 ± 213** 
Adipose tissue in wound 
tissue [%] 
7.4 ± 2.6 32.1 ± 10* 7.2 ± 2.4 34.2 ± 4.2** 
Crust thickness [m]  421 ± 47 806 ± 59** 280 ± 29 915 ± 176** 
Epithelial tongues [mm] 2.1 ± 0.2 3.2 ± 0.2* 2.3 ± 0.1 3.4 ± 0.2** 
Tab. 20: Histological assessment of uninjured skin and wound tissue on day 10 in ZDF rats. Data are 
shown as means ± SEM. *: p<0.05, **: p < 0.01 (diabetic animals compared to non-diabetic controls, 
n = 5). Length of epithelial tongues is a sum of epithelial tongues lengths from both sides of 







Fig. 26: Histological and immunohistochemical image of skin and wound tissue, blue trichrome-staining (1x magnification), A: skin on day 0, B: wound tissue 
on day 5, C: wound tissue on day 10, D: healed wound - scar on day 30. D - diabetic, ND - non-diabetic, e - epithelium, d - dermis, m - muscle layer, c -crust, g - 





5.2.8 Analysis of scar tissue 
The wounds were closing by secondary intention, with significant contraction and 
resulted in the formation of scar tissue (Fig. 27) composed of newly formed collagenous 
tissue covered with new epithelium.  
 
Fig. 27: Photographs of healed wounds – scars on day 30. Note that diabetic scars are larger than scars 
of non-diabetic animals. ND stands for non-diabetic, D stands for diabetic. 
 
The healed diabetic scars were thinner (Fig. 26D). Scars formed only 26% and 15% 
of original wound surface in non-diabetic males and females respectively (Tab. 21). Scar size 
in diabetic animals was significantly increased: by 40% in males and by 140% in females 
(Tab. 21, Fig. 27). Contribution of epithelization on overall healing is equal to scar size 
(Fig. 28). Thus it was concluded that epithelization made significantly increased contribution 
to wound repair in diabetic animals (Tab. 21), most notably in diabetic females.  
 




















epithelization to overall 
healing (scar size) n = 6,  
[% of original wound area] 
26 ± 2 37 ± 2 ** 1.4 15 ± 2 36 ± 3 ** 2.4 
Contribution of contraction 
to overall healing. n = 6,  
[% of original wound area] 
74 ± 2 63 ± 2 ** 0.85 85 ± 2 64 ± 3 ** 0.75 
Fresh scar strength,  
n = 4, [g/mm] 
71 ± 5.8 39 ± 8.3 * 0.55 47 ± 3.6 26 ± 3.2 * 0.55 
Tab. 21: Contribution of contraction and epithelization to overall process of wound repair. 
% epithelization = size of scar/size of original wound, % contraction = 100% – % epithelization. Data 
are means ± SEM. *: p < 0.05, **: p < 0.01 (diabetic compared to non-diabetic). D (diabetic), ND 
(non-diabetic). 
5.2.9 Hydroxyproline  
Hydroxyproline content per gram of wet tissue was lowered significantly in the skin 
of diabetic females. Accumulation of hydroxyproline during diabetic wound healing on days 5 
and 10 was lowered to approximately half that in healthy controls (Tab.  22). Lowered 
accumulation could be caused by lower collagen production or more likely by partial 
expulsion/substitution of fibrous tissue by adipose tissue in wounds (Fig. 26 B,C).  
 
Experimental group Day 0 - skin Day 5 Day 10 
Non-diabetic males 19.6 ± 1.42 3.33 ± 0.36 7.10 ± 0.85 
Diabetic males 17.6 ± 1.42 1.61 ± 0.56 * 2.68 ± 0.41 ** 
Non-diabetic females 24.5 ± 3.54 2.27 ± 0.15 5.17 ± 0.51 
Diabetic females 10.9 ± 2.54 * 1.21 ± 0.46 * 3.15 ± 0.28 ** 
Tab.  22: Concentration of hydroxyproline (mg/g of wet tissue) in skin and wounds. Data are shown 
as means ± SEM. n = 4 - 6 (day 0, day 5), n = 9 - 11 (day 10). *: p < 0.05, **: p < 0.01 (diabetic 






5.2.10 mRNA analysis: DNA-arrays and real-time RT-PCR.  
Using DNA-array analysis, simultaneously studying expression of 115 genes, it was 
shown that gene expression differed between diabetic and non-diabetic animals in wound 
tissue on day 10. In diabetic males the most up-regulated mRNAs were those of IL-6 and 
PAI-1, while tropoelastin mRNA was down-regulated (Tab. 23) when compared to controls. 
In female wounds the expression pattern was different. The mRNA levels of MMP-3 and 
MMP-13 were notably up-regulated in the diabetic group (Tab. 24). Other significantly 
changed gene expressions are shown in Tab. 23 and Tab. 24.  
 
Gene – males 
mRNA expression ratio of 
diabetic to non-diabetic 
animals 
Interleukin-6 (NM_012589) 1.38 * 
Plasminogen activator inhibitor-1 (NM_012620) 1.23 
MMP-3 (stromelysin-1, NM_133523) 1 
MMP-13 (collagenase-3, M60616) 0.94 
Tropoelastin (NM_012722) 0.71* 
MMP-12 (macrophage metalloelastase,  NM_053963) 0.68* 
Interleukin-10 (NM_012854) 1.15* 
Tab. 23: Relative gene expression of selected genes in granulation tissue in males on day 10 as 
assayed by DNA array (totally assayed 115 genes), ratio = gene expression in diabetic animals/gene 







Gene – females 
mRNA expression ratio of 
diabetic to non-diabetic 
animals 
Interleukin-6 (NM_012589) 0.93 
Plasminogen activator inhibitor-1 (NM_012620) 1.20 
MMP-3 (stromelysin-1, NM_133523) 2.52** 
MMP-13 (collagenase-3, M60616) 1.5** 
Tropoelastin (NM_012722) 0.96 
iNOS (nitric oxide synthase 2, inducible, NM_01261) 0.69 * 
Laminin gama 2 (XM_213902.4) 0.4 ** 
calgranulin B (MRP14, NM_053587) 0.79* 
Plasminogen (NM_053491.1) 0.73 * 
Tumor necrosis factor alpha (NM_012675) 0.72 * 
Tab. 24 : Relative gene expression of selected genes in granulation tissue on day 10 in females as 
assayed by DNA array (totally assayed 115 genes), ratio = gene expression in diabetic animals/gene 
expression in non-diabetic animals, n = 7 - 8, *: p < 0.05, **: p < 0.01 (diabetic animals compared to 
non-diabetic controls). 
 
As shown by real-time PCR analysis, the mRNA levels of IL-6, myeloperoxidase (MPO), 
p22-phox and rac2 subunits of NADPH-oxidase were up-regulated in males on day 10. 
The expression of tropoelastin and type I procollagen was down-regulated (Tab. 25). 
In females, the levels of IL-6, MPO, MMP-3 and MMP-13 were substantially up-regulated in 















Inflammation   
Interleukin-6 (NM_012589) 3.30 * 2.76 * 
Interleukin-1β (NM_031512) 1.54 1.15 
Connective tissue metabolisms   
Plasminogen activator inhibitor-1 
(NM_012620) 
1.17 1.17 
MMP-3 (stromelysin-1, NM_133523) 1.33 5.70 ** 
MMP-13 (collagenase-3, M60616) 1.31 1.99 * 
Tropoelastin (NM_012722) 0.39 * 0.83 
Type I procollagen alpha II (NM_53356) 0.7* 0.85 
Metabolism of reactive oxygen species   
Myeloperoxidase (XM_220830) 2.40 ** 4.10 ** 
P22-phox –NADPH oxidase (NM_024160) 1.39 * 1.04 
Rac2-NADPH oxidase (NM_001008384) 1.64 ** 1.11 
Tab. 25: Relative gene expression of selected genes in granulation tissue on day 10 as assayed 
by quantitative RT-PCR, ratio = gene expression in diabetic/gene expression in non-diabetic animals, 
n = 10 - 14. *: p < 0.05, **: p < 0.01 (diabetic animals compared to non-diabetic controls). 
5.2.11 Immunohistochemistry 
5.2.11.1 Myeloperoxidase and interleukin-6 
Immunohistochemical staining showed increased MPO (Fig. 29A, B) and IL-6 
(Fig. 29C, D) positive signals at the very top inflammatory layer of diabetic wounds. This 
layer was composed mainly of pus and wound exudate.  IL-6 positive signal was found 
in immune cells (Fig. 30A) and in granulation tissue fibroblasts. MPO was found in PMN 
cells and macrophage-like cells (Fig. 30B, C).  
5.2.11.2 Matrix metalloproteinases 3 and 13 
MMP-3 staining was more intense in wound tissue of diabetic females compared 
to control (Fig. 29G, H). Wound fibroblasts located on the top of granulation tissue under 
inflammatory layer were MMP-3 positive (Fig.  31D). Some immune cells and giant cells 
were also positive (Fig.  31C). The tip of the epithelial tongue was MMP-3 negative or very 






MMP-13 staining was elevated in granulation tissue of diabetic females compared to control 
(Fig. 29E, F). MMP-13 was strongly positive in the epithelial cells at the bottom of the new 
epidermis leading edge (Fig.  31B). These positive epithelial cells were in contact with 
granulation tissue and were present in all studied groups. Fibroblastic cells inside the top layer 
of the granulation tissue were also MMP-13 positive and were parallel to would surface (Fig.  






Fig. 29 : Immunohistochemical image of wound tissue, peroxidase staining, wound on day 10 (4x magnification). A: Interleukin-6 in non-diabetic male wound, B: 
Interleukin-6 in diabetic male wound, C: Myeloperoxidase in non-diabetic wound, D: Myeloperoxidase in diabetic wound, E: Collagenase-3 (MMP-13) in female 
non-diabetic wound, F: MMP-13 in female diabetic wound. G: Stromelysin-1 (MMP-3) in female non-diabetic wound, H: MMP-3 in diabetic female wound. e - 










Fig. 30: Immunohistochemical image of wound tissue, peroxidase staining, wound on day 10 (60x magnification). A: Interleukin-6 in immune cells, B: 
myeloperoxidase in PMN cells, C: myeloperoxidase in macrophage-like cells in the wound pus, D: granulation tissue - negative control without antibody. 






Fig.  31 : Immunohistochemical image of wound tissue, peroxidase staining, wound on day 10 (60x magnification). A: MMP-13 in fibroblast-like cells on the top of 
granulation tissue, B: MMP-13 in epithelial cells at the tip of newly forming epithelial tongue, C: MMP-3 in multi-nucleated giant cell in the granulation tissue, D: 






6.1 Part 1: Hyaluronan, Hyiodine - a potential for wound healing 
Hyiodine, the combination of hyaluronate and iodine, is a novel product combining 
high m.w. HA and iodine. It was reported that the complex of hyaluronate-iodine had 
beneficial effect on wound repair in diabetic foot ulcers and hard-to-heal wound of different 
etiology (Sobotka et al. 2006; Sobotka et al. 2007). However, the exact mechanism of its 
action on wound repair is unknown. High m.w. HA has beneficial effects on wound healing 
(Balazs et al. 2000). It is highly viscous and when it was applied on rat skin wounds in our 
experiments, it made wound redressing easier because Hyiodine soaked gauze did not stick to 
the wound. Hyiodine applied on the wounds immediately after skin excision accelerated 
wound contraction in the first days of healing. Later on the course of wound closure was 
similar in the Hyiodine-treated and saline-treated group. The influence of added HA may be 
greatest in the proliferative phase of healing. The antiseptic properties of iodine may be more 
important in humans than in rats.  
Wounds treated with Hyiodine showed thickened epithelium on day 7. HA is a component of 
granulation tissue but its synthesis is not limited to mesenchymal cells. HA is contained 
in normal epidermis and it is synthesized by epidermal keratinocytes. Epidermal injury 
activates hyaluronan synthases in keratinocytes and causes an increase in epidermal HA. 
Keratinocyte migration is retarded when hyaluronan synthesis is blocked (Tsuboi et al. 1992). 
Exogenous HA may support epithelial hyperplasia (Arnold et al. 1995). The role of iodine in 
wound healing is not clear (Selvaggi et al. 2003), but PVP-iodine hydrogel was reported to 
improve epithelialization (Vogt et al. 2006).  
Hyiodine application did not change collagen accumulation in the granulation tissue. 
The expression of other ECM components, proteinases and cytokines was not changed when 
studied on mRNA level. Together, expression of 92 genes were studied, however it is now 
known that thousands of genes are differentially expressed during the wound repair 
in comparison to uninjured skin (Roy et al. 2007; Roy et al. 2008; Greco et al. 2010). 
It is possible that several important targets had been missed in our selection. Therefore, for the 





Iodine greatly potentiated the ability of HA1200 to stimulate exudate formation. The protein 
composition of the exudate reminded of that of rat plasma with a prominent albumin band 
suggesting that a large part of exudate came from the plasma. Uronic acid content 
in the exudate was also increased. HA is a normal component of wound fluid, but plausibly 
some HA applied on the wound have been retained on its surface. The nature of the 
interaction between iodine and HA is not clear. Iodine may bind to the glycosaminoglycan or 
it may oxidize it. The action of HA may be more powerful or its absorption may be slowed 






6.2 Part 2: Characteristics of cutaneous healing of diabetic and obese 
ZDF rats 
ZDF rat is a well-known model of type II diabetes with obesity. This work shows 
characteristics of skin repair in ZDF male and female rats. Wound size diminution was 
impaired by DM and obesity in both sexes. The start of the closure was slightly slower 
in females and wound size increased significantly in the first phase of wound repair in 
diabetic females. This could be caused by the relatively higher wound severity due to the 
smaller body size of females, different diet, different skin composition or hormonal 
distinction. Diabetic animals had different skin composition, containing more adipose tissue 
compared to non-diabetic counterparts.  
Diabetic wounds were accompanied by inflammation and were covered by larger crusts. 
During the healing, diabetic wounds were filled with a large amount of adipose tissue, poorly 
filled with granulation tissue and their contraction was impaired. Whereas non-diabetic 
wounds were almost entirely closed by contraction, in diabetic wounds, the epithelization had 
a more pronounced contribution to repair. Consequently, diabetic animals developed larger 
scars. Different fibroblast phenotype in adipose as opposed to dermal tissue could provide 
different paracrine stimulation of epithelium. Adipose tissue could influence wound healing 
by limiting cell migration or by its adipokine production. The retardation in contraction could 
be mediated through physical changes such as tension in skin due to obesity. The organization 
of fibroblasts and myofibroblasts network could be impaired by abundant adipose tissue 
(Goodson et al. 1986; Bauer et al. 2004). Generally speaking, wound healing in humans is 
known to be accomplished mainly by granulation tissue formation and epithelization with 
little wound contraction. Thus healing with increased contribution of epithelization that was 
observed in diabetic animals resembles partially this manner of healing.  
Lower hydroxyproline concentrations and slightly lower type I collagen mRNA expression in 
granulation tissue was most probably caused by a displacement of collagen producing 
fibroblastic cells by adipocytes. The study of obese insulin resistant JCR rat showed impaired 
wound repair, contraction and wound collagen content (Bauer et al. 2004) comparable to our 
results. In our study, diabetic males had very high increase in blood glucose and relatively low 
increase in body weight. On the other hand, diabetic females showed a high increase in body 





observed impaired wound repair in both sexes and therefore we propose that both factors 
(high obesity and high glucose) had negative effect on wound repair. Most probably the 
combination of high obesity and high glycemia would result in even higher impairment of 
wound repair due to cumulating effect. Together their study (Bauer et al. 2004) and our study 
suggest that obesity significantly impairs wound healing and that this parameter is as least 
as important as hyperglycemia. On the other hand, similar work on db/db mice concluded that 
the variability of wound closure for individual mice did not correlate with severity of obesity, 
hyperglycemia, hyperinsulinemia, or insulin resistance (Trousdale et al. 2009).  
We noticed a substantial difference in healing between bandaged and non-bandaged (open) 
wound. The bandaging increased the contraction in early phases of wound repair. This could 
be caused by the tension of the bandage, a barrier being formed against particles or microbial 
infection, wound moisture retention or exudate removal support. On the other hand, a bandage 
could cause animal stress. Animals had a natural tendency to scratch and to try to remove the 
bandage. As a result of these conditions the animals sometimes decreased their weight by up 
to 10% when bandaged. Furthermore, anesthesia was needed at every change of dressing and 
the fragile tissue adhering to the gauze pad could have been damaged. A portion of the crust 
that merged with the gauze was removed during the dressing change.  
ZDF rat differs from other diabetes rodent models. Although type I DM is clinically less 
frequent when compared to type II, streptozotocine-induced type I diabetic rodent is the most 
widespread model for experimental research of diabetic wound. This model has limitations 
such as potential kidney, liver, pancreas toxicity of streptozotocine, and impaired weight gain 
(Greenhalgh 2003). An obese type II diabetic db/db mice, exhibited severe wound healing 
impairment compared to streptozotocine-induced diabetic mouse, which healed quite 
similarly to control non-diabetic mouse (Keswani et al. 2004; Michaels et al. 2007). Rate of 
wound area diminution was also similar between diabetic and non-diabetic rat in recent study 
(Dogan et al. 2009). In our work, epithelization played an important role in diabetic rats, as 
wound contraction was impaired. The length of epithelization tongue was increased. Increased 
epithelization could be caused by high levels of insulin (Apikoglu-Rabus et al. 2010) present 
in diabetic ZDF rats. Therefore the use of the present model for studying impaired 
epithelization is limited. The model we report could be modified for further studies by 
lowering rat insulin levels. Also increased leptin levels in diabetic rats could play a role in this 
phenomena, as leptin influences epithelial cells in vitro and in vivo and epithelial tongue in 





was severely disturbed (Wall et al. 2002) and leptin levels were reported to be increased 
(Sahai et al. 2004) alike in ZDF rats. This difference in epithelization could be explained by 
different mutations of LEPR in ZDF fa/fa rats and in db/db mice (C57BL/KS-Leprdb/J). In 
ZDF rats there is a point missense mutation in residue 269. A protein with leptin binding 
activity and intact signaling domain is produced, however with dimer formation impairment 
(Phillips et al. 1996). In the case of db/db mice an aberrant splicing variant of LEPR with a 
106 nucleotides insertion and prematurely terminated dysfunctional intra-cellular domain is 
present (Chen et al. 1996). This suggests that leptin dependent epithelial cell promotion might 
be functional in ZDF rats (due to probable different mechanism of LEPR formation and 
function in epithelial cells than in the hypothalamus) and dysfunctional in the case of db/db 
mice (due to a missing intracellular domain in the receptor). To prove this hypothesis it would 
be necessary to do another in vivo study and to compare the responsiveness of cutaneous 
epithelial cells from ZDF rats and from db/db mice to leptin.  
Our study showed different patterns of the expression of several genes, some of them 
connected to inflammation, thus supporting observed abundant inflammation in diabetic 
animals. However, the question of whether diabetic wounds are inflamed due to deregulated 
endogenous inflammation control or higher susceptibility to microbial infection remains 
unresolved. We have shown increased expression of IL-6 in diabetic wounds and established 
its spatial distribution on the very top of the wound. Surprisingly, the levels of adipokine IL-6 
in the plasma of both healthy and diabetic unwounded animals were similar even in diabetic 
females, whose body weight was double that of their non-diabetic counterparts. The role of 
IL-6 is complex. IL-6 is essential in the regulation of early immune response to trauma that is 
necessary for proper wound repair (McFarland-Mancini et al. 2010). It is produced by 
fibroblasts, keratinocytes, neutrophils and macrophages (Mateo et al. 1994) and its deficiency 
leads to impaired healing (Lin et al. 2003; McFarland-Mancini et al. 2010). However, a surfeit 
of IL-6 can slow down tissue repair (Gallucci et al. 2001) and decrease fibroblast proliferation 
(Mateo et al. 1994). IL-6 levels were elevated in patients with diabetic ulcers (Fu et al. 1999). 
It can be extrapolated from the research on liver regeneration, where a short-term application 
of IL-6 was shown to be beneficial and a prolonged application negative, that a prolonged 
expression of IL-6 in diabetic wounds might also be detrimental to wound healing. In contrast 
to our results, the IL-6 levels were suppressed in wound fluids of streptozotocine-diabetic 





We have observed higher levels of MMP-3 and MMP-13 mRNA, and immunohisto-chemical 
signal in diabetic females. Abundant expression of metalloproteinases could be partially 
responsible for lower collagen (hydroxyproline) content in diabetic wounds. MMP-13 
degrades native fibrilar collagens and to some extent proteoglycans and other extracellular 
matrix components while the main substrates of MMP-3 are gelatin, laminin, fibronectin 
and proteoglycans. Over-expression of wound MMPs can lead to proteolytic tissue damage 
(Lobmann et al. 2002). In chronic wounds, MMP-3 was expressed by keratinocytes located 
above the basement membrane behind the leading edge of the hyperproliferative epithelium 
and was also detected in the granulation tissue (Saarialho-Kere et al. 1994). In our 
experiments, MMP-3 was not present in the epithelium, but we have detected MMP-3 in the 
granulation tissue in rats. MMP-3 has a role in wound contraction and activation of the 
contraction phenotype in fibroblasts (Bullard et al. 1999). In vitro, MMP-1 and MMP-3 can 
be induced by a shock via IL-6 autocrine stimulation in dermal fibroblasts (Park et al. 2004) 
and IL-6 can increase the MMP-13 gene expression in rat fibroblasts (de la Torre et al. 2005). 
We hypothesize that the abundant presence of IL-6 in diabetic wounds could cause the 
increased expression of MMP-3 and MMP-13. As MMP-1 is not present in rat tissues, rat 
MMP-13 is considered to play a predominant role in matrix degradation, comparable to the 
role of MMP-1 in humans (Okazaki et al. 2001). In chronic human wounds, MMP-13 was 
detected exclusively in fibroblasts in deep wound bed and not in migrating keratinocytes 
(Vaalamo et al. 1997). MMP-1 is produced by migrating epithelial cells (Parks 1999). In ZDF 
rats, MMP-13, playing similar role as human MMP-1, was clearly detected in keratinocytes 
located near wound edge and in upper layers wound fibroblasts. Also MMP-8 (neutrophil 
collagenase) and MMP-9 (type IV collagenase) were elevated in human chronic wounds in 
comparison to early acute wounds (Lobmann et al. 2002). In our study, we did not observe 
increased MMP-9 or MMP-8. MMP-9 is required for normal progression of wound closure 
(Kyriakides et al. 2009). However, its abundant presence was shown to interfere with 
epithelization, basement membrane and keratinocyte migration (Reiss et al. 2010). The reason 
why we did not observe impairments in epithelization could be partially explained by the 
finding that MMP-9 levels were normal in diabetic rats. The limitation of our study is that 







7.1 Conclusion – Part 1 
Positive action of hyaluronan-iodine complex observed on hard-to-heal wounds 
in diabetic patients was supported by our animal model study. Hyiodine speeded up the 
process of wound closure in the early phase of healing. The positive effect could be mediated 
by an effect on wound epithelium. Accentuated exudation keeps the wound moist and makes 
wound redressing easier. The influence of HA is supported by iodine that was not only a mere 
disinfectant but potentiated some effects of HA. The formation of granulation tissue and its 
main component, collagen, was not changed as was not the mRNA expression of the set of 
studied genes. 
7.2 Conclusion – Part 2 
The present work revealed an impaired mode of cutaneous healing, and the structure 
of wound tissue in obese diabetic and lean non-diabetic ZDF rats. This model could be useful 
for further studies of molecular changes in wound repair caused by obesity and diabetes. 
The reported results warrant further research into the regulation and resolution of 
inflammation response, the role of adipose tissue, the deregulation of MMPs during wound 
repair in ZDF rats. Also the role of leptin and its receptor in epithelization could be studied on 
molecular level. Obese ZDF rats seem to be a suitable model for the testing substances 
designed to influence tissue repair and are proposed as a novel model of impaired cutaneous 
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